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Abstract
The biomanufacturing industry is changing due to increasing globalization. However, it is
changing differently from other high tech industries like software/ semiconductor/ automo-
biles. In this study we use global biomanufacturing investment data, industry survey data
as well as interviews with members of industry and academia to understand the extent of
microbial biomanufacturing activity (total volume, number of facilities, type of facilities)
and nature of biomanufacturing activity (complexity of products and processes across both
mammalian and microbial production) in different regions of the world today.
The study shows that traditional centers of expertise in US and EU still house most of the
worlds biomanufacturing capacity. The facilities in US and EU perform a larger number of
operations within their facilities and also more technically complex operations than facilities
in Asia. US facilities support the most complex products (median unit operations =13)
and processes (cell culture, purification) and maximum average products per facility(12.2).
Asian facilities support simpler products (median unit operations =7), simpler processes
(fermentation, fill/finish) and fewer products per facility on average (3.25).
These results support the idea that managing technical complexity is one of the biggest
challenges in biomanufacturing today and it can determine where a biologic can be man-
ufactured. While economic forces push manufacturing of biologics to low cost locations,
the need to develop expertise may prevent manufacturing from scattering across the world.
Instead, there may be a more guided flow to locations with an expertise in certain types of
products and processes.
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Chapter 1
Introduction
The National Research Council defines globalization as 'the expanding international
flow of capital goods, knowledge and people' [22]. Since 1990 trade flows have grown
faster than the world's GDP. In the National Intelligence Council's most recent report
on future global trends, globalization is referred to as 'a mega-trend ... [and] a force
so ubiquitous that it will substantially shape all the other major trends in the world
of 2020.' [30]
In terms of size, speed and direction of flow, the force of globalization is unprece-
dented in modern history. [22] Lower costs combined with government policies have
shifted the locus of most manufacturing and some service industries to other parts
of the world [16]. Many products use globally sourced materials and flow through
multiple processes that end in products assembled in locations far away from the
location of manufacture of its components. [11, 26]
In the recent years, the bio-pharmaceutical industry has been a witness to this
globalization. "There has been a perfect storm - more products, more manufacturers,
more countries and more access" said Commissioner of Food and Drugs Margaret A.
Hamburg, M.D. "Global production of FDA-regulated goods has exploded over the past
ten years." [12]
This is an industry that began in the 1980s with the development of recombinant
technology. Biotechnology has been used to make bread and wine for centuries. The
advent of recombinant technology has allowed the industry to scale production of
proteins which were earlier derived from animals. Advances in genetic engineering
have allowed the production of many more biotherapeutic molecules of different types,
shapes and complexity than was possible before. The US has been a pioneer in bio-
therapeutics and is still a global leader. However, with globalization of the industry,
important structural changes taking place in the industry that may challenge this
predominance.
Globalization of high-tech industries like software [1], semiconductors [19] and
pharmaceuticals [5] has been studied in detail. These industries have undergone a
global shift in production activities as well as a modularization of activities termed
vertical specialization . Vertical specialization is defined by Macher et al. as 'the
development of an industry structure populated by firms that specialize in one or
a limited set of activities who contract with other firms that specialize in different
activities in the region.' [18, 23]
In the past, most biopharma companies have been highly vertically integrated in
all functions from R&D, through process development, manufacturing and marketing.
This supports the product cycle model where US firms develop new products for
the domestic market. As the product and/or technology matured, it eventually is
manufactured offshore in cheaper locations. [31, 25].
The first approved biotech drugs in the mid-1980s stayed onshore for 20 years
before production was moved to a low cost location [25]. However, the pace at which
the biopharmaceutical industry has been globalizing indicates that firms may not be
waiting for products to mature to move the manufacturing offshore. "In addition to
an increase in imported finished products, manufacturers increasingly use imported
materials and ingredients in their U.S. production facilities, making the distinction
between domestic and imported products obsolete" said Commissioner of Food and
Drugs Margaret A. Hamburg, M.D in a press release in June 2011. [12]
Critics of the product cycle model believe that using global production networks
would allow firms to gain maximum efficiencies by allowing firms to specialize within
their specific range of skill, knowledge or ability. [18]This vertical specialization is
beginning to emerge with the rise of contract manufacturing. Much of the growth
of the industry however, is 'cluster driven' 1 [6, 13], though the number of clusters
have been increasing both within the United States and outside it [17]. This may
be attributed to the fact that the knowledge production process in biotechnology and
related industries have spillover effects in the region [13] as well as over time.
The persistence of 'cluster driven innovation' is unique to the biotechnology indus-
try and differentiates biomanufacturing from other traditional manufacturing sectors
like semi-conductors and automobiles and make it an interesting topic of study. Many
studies have looked at the factors that affect biotech clusters and innovation within
these clusters. Studies claim that new clusters perform low-value and low margin
activities while they catch-up with the leading clusters that exist in US today [17].
The idea that complexity of manufacturing determines its globalization has been
suggested in many studies. There have been many studies comparing the difference in
the extent of innovative activity across biotech clusters (through number of patents,
VC investments and number of new startup firms). Other studies have also illustrated
how geographic proximity, organization and processes affects the flow of knowledge
through a network [3, 8]. Some studies have suggested that biotechnology industries
have clustered based on the strength of the science and technology base [29]. There
is sparse literature that explores how the complexity (diversity and specialization) of
technology itself varies across various geographic locations in science based clusters
[9].
1.1 Globalization and Biomanufacturing
Complexity of technology is central to the operations of a manufacturing facility. Ex-
tending the biotechnology argument to biomanufacturing, one can expect the com-
plexity of biomanufacturing operations to vary between US facilities, EU facilities
and Asian facilities.
For biomanufacturing, globalization brings forth some unique challenges to the
'Porter defines clusters as a geographically proximate group of interconnected companies and
associated institutions in a particular field, linked by commonalities and complementarities.
Figure 1-1: Number of foreign sites manufacturing FDA approved drugs has
doubled between 2001-2007
Number of Foreign Facilities Making FDA RegulatedF Drugs
2001 2002 2003 2004 2006 2006 20071 Year
Source: FDA,2011 [11]
industry as well as the regulators. [Figure 1-1] shows the number of foreign sites
manufacturing FDA approved drugs has doubled from 2001-2007. As the biopharma-
ceutical industry grows in importance, the globalization of biomanufacturing becomes
increasingly relevant to different stakeholders today for a variety of reasons:
e Local Innovation and Regional Competitiveness: In order to focus on core com-
petencies many firms choose to out-source low value added activities. This may
eventually lead to outsourcing of R&D operations. Many fear that sophisticated
engineering and manufacturing capabilities that underpin innovation in a wide
range of products have been rapidly leaving too, as a result of this trend. Pisano
and Reynolds both point to a growing concern that the US 'has lost or is in
the process of losing the knowledge, skilled people, and infrastructure needed to
manufacture many of the cutting-edge products it invented.' [24, 25]
" Quality and Safety of Drugs: The decision to balance the advancements in
cutting-edge technology and the upholding the standards of quality and safety
is made more tenuous in a rapidly changing global industrial landscape. Con-
cerns of quality and safety have increased over the past years as more drug
recalls and adverse events have been reported. In 2001 in a statement before a
Senate committee, Bernard Schwetz listed inspection activities and drug-related
u3,000
S2,000
~~1,600
o1,000
500
2,04,
adverse events among the challenges that the FDA faces in the 21st century.
* Regulatory Challenges: Over the past decade, the sheer number and unique
geographic locations of biopharmaceutical manufacturing facilities requiring in-
spection has increased substantially. Many new biopharmaceutical manufactur-
ing sites have been established - several in China and India. New sites in China
and India represent more than 40% of FDA-registered foreign pharmaceutical
locations - making inspection and oversight increasingly costly and cumber-
some [34].
Table 1.1: Cost of Foreign vs. Domestic Inspections - The average cost of
foreign inspections is two times the cost of a domestic inspection.
Average Cost of FDA Inspection (approx)
Domestic Foreign
$23,000 $52,000
Source: FDA,2011 /11]
Figure 1-2: Number of FDA inspections is falling over time
FDA, 2011 [11]
Inspection of an international facilty costs the FDA almost twice the cost of
inspecting a local facility [Table 1.1]. Budget cuts have resulted in severe
shortfalls in the FDA budgets [32]. In their special report released in June
2011, the FDA admitted that it does not have the resources to keep pace with
the pressures of globalization given the breadth and complexity of the industry
that it is regulating. Even with a risk-based approach, at the current rate of
inspections, it would take nine years for the FDA to inspect every high priority
pharmaceutical facility just once. [11]
e National Health Security: Without any manufacturing in the country, govern-
ments fear that in times of crisis they will not be able to manufacture drugs
locally to meet the demands of its people and will be at the mercy of other na-
tions in time of need. Recent epidemics of swine flu and bird flu have brought
to attention the need to be able to manufacture large amounts of drugs and
vaccines for the population [20]. In 2010, 178 drug shortages were reported to
the FDA, in 2005 this number was only 61. The drugs recalled include can-
cer drugs, anesthetics used in surgery, a large number of "sterile injectables" -
medicines that are given intravenously - and "crash cart" drugs used in emer-
gency treatments [4]. The FDA blamed quality and manufacturing problems
that led to recalls of the drugs.
Figure 1-3: The number of drugs facing shortages is steadily increasing
Number of Drug Shortages in United States
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*2010 numbers do not include shortages of vaccines and products made from blood, tissue
and other biological sources. FDA said the number would be even higher if shortages for
those products were also added in. [4]
One of the main challenges in studying the biomanufacturing industry is the avail-
ability of data. Much of the data is proprietary and there is no single source of data
or unambiguous approach to study the globalization of the industry. This study
aims to provide some insight into the nature of biomanufacturing activity in different
locations (US, EU, Asia).
1.2 Thesis Objectives and Approach
The study is divided into two parts.
The first part of this thesis builds upon an earlier study by Reynolds on the trends
in globalization of mammalian biomanufacturing in the world today [25]. This study
was conducted through the Industrial Performance Center(IPC) and aims to provide
a high level picture of the rapidly evolving global microbial manufacturing landscape.
This section is not intended to be comprehensive, but to illustrate the extent to which
advanced technologies are being developed and disseminated worldwide. For example
" Where are the main microbial manufacturing facilities in the world ?
" Where are the newer facilities being added?
" Where is the newer capacity being added and by whom?
" What are the major trends microbial manufacturing that are of interest to in-
dustry leaders?
Microbial manufacturing is a mature technology so one may expect to find much
of the manufacturing activity to have moved to low cost locations. We do find a
trend in vertical specialization with emergence of contract manufacturing especially
in Asia. However, we find that Europe and US still play a major role in terms of
both capacity and number of firms. This contradicts the 'product life cycle' theory
and suggests that factors other than the maturity of technology and market are at
play that may need companies to keep manufacturing located primarily in Europe
and US. Complexity of the process, the need for highly skilled workers, and large
costs in setting up facilities, among many others, are likely to play a large role in the
manufacturing activity of different locations.
The second part of the study tries to better understand how complexity of the
technology affects manufacturing activity in different locations. Biomanufacturing
activity varies widely across regions and facilities. Even within facilities, a range of
operations and processes can be supported that vary in number and complexity. In
this study, we look both the number of operations and processes and the complex-
ity of these operations to compare manufacturing activity. Using data and metrics
embedded in the manufacturing processes and engineering principles we attempt to
answer the following questions:
* How do facility characteristics and organization vary by location in the industry?
* How do biologic products manufactured vary by location?
" How does the approach to quality and safety vary by location?
" How do quality issues in biomanufacturing vary by location ?
Unlike other industries, biomanufacturing complexity cannot be defined by a few
metrics. I use facility level information (number of products, capacity utilization,
age of the facility), process information (organization of employees across different
manufacturing activities, processes supported) and product level information (number
of unit operation for each of the products manufactured in the facility, quality issues
faced during product development and manufacturing) to get a finer understanding
of manufacturing activity within facilities. The data indicates that facilities in US
and EU support more processes for more products and markets than Asian facilities.
Manufacturing facilities in US and EU specialize in upstream, innovative processes.
The individual processes in US and EU are also more complex than processes in Asian
facilities.
Details on manufacturing activity within facilities is proprietary. I am using pre-
liminary data gathered from a survey conducted by the Center for Biomedical Innova-
tion(CBI) at MIT as a part of a larger study to understand the impact of globalization
on regulatory compliance and quality approaches. The survey is still underway at the
time of writing of this thesis. My analysis includes data from 14 facilities across USA,
Europe and Asia. The number of facilities used in this study may not be sufficient
to cover the breadth of manufacturing across the world. However, the data set is
rich in its depth of information on manufacturing activities in facilities. The analysis
provides interesting insights to biomanufacturing in different locations of the world
and highlights patterns that would be interesting to study in detail in the future once
more data is collected.
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Chapter 2
Methods and Limitations of Study
Information on local production as well as the number and capacity of drug substance
and drug product suppliers is very fragmented and possibly proprietary. In particular,
both Active Pharmaceutical Ingredient (API) suppliers and generic manufacturers in
the U.S. and Europe require their activities to be confidential and secret, lest their
preparations for filing dossiers for generic market approval become known to the
branded manufacturers.
In the case of this research, I have used data from available databases and in-
dustry wide survey for analysis. I turned to qualitative semi-structured interviews
and discussions with focus groups comprising of MIT faculty (academia), industry
experts at Center for Biomedical Innovation (CBI), members of the Massachusetts
Biomanufacturing Roundtable (industry) and representative of Massachusetts Tech-
nology Collaborative(MTC) (policy makers), to interpret and provide context to some
of the observations of the data.
2.1 Study of the Microbial Biomanufacturing Land-
scape
The first part of the study looks at the global microbial biomanufacturing land-
scape. This research project was funded by the Massachusetts Technology Collab-
orative (MTC) to analyze global microbial production data and determine trends
in the industry with respect to location and technological change, and determine to
what extent Massachusetts is or could be competitive in microbial production. This
project was a continuation of an earlier study of mammalian production conducted
by Reynolds [25]. In this study, I have used a data set similar to the mammalian
study.
The data set for microbial production was provided by BioProcess Technology
Consultants (BPTC), a biopharmaceutical consulting firm based in Woburn, Mas-
sachusetts. BPTC specializes in process and product development; manufacturing;
quality and regulatory affairs for biologics. Their clients include all of the major bio-
pharmaceutical firms as well as midsize companies in the US and abroad. The firm
maintains both demand side and supply side databases related to biomanufacturing.
The information provided in the data set by BPTC was gathered from public sources
including trade magazines, corporate documents and newspapers. The company also
publishes an annual industry report outlining the state of global supply and demand
for biomanufacturing and current trends. These databases are described in detail in
the following sections.
2.1.1 Facility database (Supply side)
BPTC maintains a database of all public announcements of new capacity, planned
capacity and when facilities go offline. The database was created in 2002 when the
firm first began tracking existing facilities and contained information about facilities
planned up until 2013. The database contains records for 150 facilities across 24
countries.
The database is fairly robust for facilities in North America (Canada and US -
60 facilities) and Europe (61 facilities) given the companies' experience and expertise
in these regions. Also, there are fairly few investments made year to year in new
facilities in this region. However, it is somewhat limited when it comes to facilities
in Asia where biosimilars are being manufactured for local and some international
markets.
The database of facilities contains the following information for each facility:
1. Company Information
2. Location of Facility (City, Country)
3. Facility Type (Mamalian / Microbial)
4. Company Type (whether a product company or a contract manufacturing or-
ganization (CMO) or Both)
5. Manufacture Type (whether it is a commercial or clinical facility)
6. Stage (whether the facility is online, in construction, in planning, or in the
validation stage)
7. Year the facility went into operation (or year estimated to be online)
8. Number of Reactors
9. Size of reactors (in liters)
10. Total volume in thousands of liters.
11. The type of processing used at the facility (batch-fed, perfusion, roller bottle,
disposable)
2.1.2 Market size database (Demand Side)
The demand database maintained by BPTC tracks biological recombinant drugs that
have been approved and those that are currently in clinical trials. The database also
includes estimated sales for each of these drugs.
The database of drugs contains the following information for each drug:-
1. Phase of Development ( Phase 1, Phase 2 , Phase 3 , Pending Approval or in
market)
2. Manufacturing Technology (Mammalian, Microbial, Other)
27
3. Company
4. Product Name US (Brand name if the product was approved in the US)
5. Product Name EU (Brand name if the product was approved in the EU)
6. Generic Name
7. Product Type (Hormone/ Antibody/ Antibody fragment (fAb)/ Cytokine etc.)
8. US Approval Date
9. EU Approval Date
10. 2008 Sales ($M)
The high level of risk and uncertainty in the drug development process makes the
predictions on the demand side more unreliable as we go beyond 2008.
2.1.3 Analysis
The analysis performed on this database was similar to that used by Reynolds on the
mammalian database. Pivot tables were used to aggregate data by different sets of
variables like geography (continent, country, state); by size in terms of facility and
volume (clinical, commercial, greater than 5kl, 10kl); by type of company (product
companies vs. CMOs); and by number of facilities. All microbial facilities were batch-
fed so the volumes of regions could be summed up. When classifying the facilities
into geographic region, Japan and Australia were grouped into Asia.
2.1.4 Qualitative Data Collection and Analysis
Quantative analysis was also supported with qualitative semi-structured interviews
to provide context to and aid in interpretation of the quantitative data. This included
12 interviews with leaders in biomanufacturing primarily around the Massachusetts
region. Many of the interviewees are leaders of large global firms that cater to interna-
tional markets and had facilities around the world including research or manufacturing
facilities in Massachusetts.
In addition to face-to-face interviews, findings and data analysis were discussed
with three focus groups, sponsored jointly by MITs Industrial Performance Center
and the Massachusetts Technology Collaborative (MTC). These meetings were held
in March, April and June 2010. Each of these meetings was attended by 12 to 25
people from industry, academia and the non-profit world and allowed for industry
leaders to vet and respond to my research. These groups served as an informal
working group of the larger effort of the Massachusetts Life Sciences Collaborative
around biomanufacturing. Findings of my research were also reported to the MTC
and the chairs of the Massachusetts Biomanufacturing Roundtable every month. In
this study, I will refer to these meetings as 'MTC interviews'.
2.2 Industry Survey of Biomanufacturing: Facility
Characteristics and Approach to Safety and
Quality
The industry survey is a part of a larger study being conducted by the Center for
Biomedical Innovation (CBI) to examine the effect of globalization on biopharma-
ceutical product manufacturing, regulatory policies, compliance and economics. The
study is funded by the Alfred P. Sloan foundation.
There is no comprehensive database available to describe the current state of
biomanufacturing processes within facilities across the world. Much of this informa-
tion is tacit and proprietary. In order to collect this information, we constructed a list
of questions that were used in an online survey to be answered by biomanufacturing
facility heads across the world.
A survey was chosen because it allowed us to capture data from facilities across
the world with the relative ease. No questions in the survey were mandatory. This
was important to ensure that the data collection was not too burdensome for the
respondents and their privacy was maintained as their participation was completely
voluntary.
The survey was created based on inputs from MIT faculty as well as leaders from
the industry. It is comprised of 6 sections
1. Facility Information - basic information about the facility.
2. Facility Organization - details about age, ownership, capacity, number of prod-
ucts manufactured, local and international markets served and regulatory au-
thorities.
3. Quality - number of employees, organization across functions, quality issues and
how they are managed.
4. Inspections - frequency and nature of inspections for each agency that the facil-
ity interacts with, perceptions of the stringency and standing, how inspections
are dealt with by different teams, etc.
5. Product Specific Questions - respondents were allowed to fill in data for up
to 5 products. Questions included information about product characteristics,
complexity, manufacturing process, quality issues faced etc.
6. Role of academia in biomanufacturing - to what extent academia can play a
role in biomanufacturing quality and safety.
A list of over 90 contacts for microbial and mammalian facilities across the world
was provided by Bioprocess Technology Consultants. This list was supplemented by
contacts in the MIT Biomanufacturing Program. All contacts were emailed with the
survey link. In addition, the study and survey were advertised in Pharma Magazine.
All the responses were voluntary, and no question in the survey was mandatory. All
responders were assured that the responses would be made anonymous for analysis.
Each responder is to receive a survey report showing them where the facility stands
against other anonymized respondents. The report aims to incentivize facilities to
respond to the survey by offering them information that they would otherwise not be
able to get from other sources.
2.2.1 Unique Challenges of Surveying Biomanufacturing
The survey of biomanufacturing facilities was based on a similar study of pharmaceu-
tical manufacturing focused on manufacturing performance of pharmaceutical manu-
facturing facilities by Macher et al. called the Pharmaceutical Manufacturing Research
Project (PMRP). The PMRP survey was used as a reference point to begin designing
questions for biologics. The survey evolved on its own into a different format based
on feedback from various members of the CBI study who served as consultants and
advisors to the group.
A large variety of operations can be categorized under the umbrella of bioman-
ufacturing. A biologic is usually a very large organic molecule that exists in various
configurations making it difficult to characterize. Inducing a biological system to pro-
duce a molecule that it doesnt normally produce in nature is a tricky business. The
complexity increases with molecule size, with host cell (microbial to mammalian) and
also with the scale of manufacture. Most processes in a manufacturing facility, like
technology transfer, manufacturing, quality assurance and packaging, are developed
based on the needs of the product and host cell. In addition to the cell culture and
purification of the biologic product, there are a wide variety of operations that are
performed and a range of skill sets that are housed within a facility. For example
regulatory affairs, quality activities, deviations and quality issues when they arise,
training, inspections etc. These functions are also unique to the product that is be-
ing manufactured in a facility, making each biomanufacturing operation unique in its
complexity and the challenges it faces.
As a result, biomanufacturing facilities are a metaphor for the biologics they man-
ufacture. They are not easy to characterize or compare. Each facility has a unique
history based on its products, ownership and organization and set up. Unlike name-
less factories in other industries, biomanufacturing facility are often addressed as 'The
finsert firm name] [insert city name] facility' indicating that they have a unique char-
acter or personality.
This made surveying manufacturing facilities a huge challenge. A wide variety of
metrics were required to get a basic understanding of the operations in the facility.
Much of the knowledge of manufacturing resides with the people performing specific
operations. This is especially relevant for compliance related information. As a result,
the survey design required inputs from people with expertise in a variety of operations.
The team designing the survey involved members from academia, industry as well
as specials employees from FDA and EMA that were associated with the Center for
Biomedical Innovation. The process of designing the survey took around 6 months.
The design process involved 4 main stages:
1. Identifying the variables that would address the research questions listed in the
Sloan proposal
2. Identifying the questions that would help extract that variable from the survey
3. Framing the question and the options based on cGMP guidelines and industry
accepted terminology
4. Setting up an online survey that would be convenient for responders to use and
beta testing
At each stage, I gathered feedback and insights into questions from the design
team. The survey that resulted was long and could also not be answered completely
by one person alone. The project team decided to address the survey to the facility
manager but allow the survey manager to forward the link of the survey to employees
who can answer specific sections of the survey.
A lot of effort was put into ensuring that the gathering of data was efficient and
convenient for the responders. A survey vendor was chosen on the basis of the feature
that allowed responders to jump from and/or skip to any section of the survey. This
would allow multiple people to respond to different parts of the survey.
Tom Ransohoff from BPTC and Steve Kennedy beta-tested the survey in February
and filled a questionnaire created for feedback. The feedback was used to trim the
survey down to 115 questions. The final survey was released April. A survey link
was emailed to a list of contacts prepared based on the contacts of BPTC and MIT
- CBI. In addition, the survey link was also provided to Pharma Magazine to email
its subscribers. [See Appendix C]
2.2.2 Survey Limitations
It is likely that if the survey has been answered by only members or contacts from
the CBI, there would be a strong bias in the sample data. Firms that associate with
MIT and CBI are likely to be firms that are academically oriented and thus highly
innovative in their functions. They are also more likely to be prominent firms in the
industry with a high level of sophistication and expertise by virtue of their association
with MIT. Emailing the survey from a large database that included facilities that were
not familiar with MIT and the CBI Sloan study ensured some amount of randomness
to the responses.
However, since there were no honoraria provided to the respondent, there is a
possibility of self-selection bias in facilities that respond to this survey based on:
Interest in globalization - Facilities interested in serving new markets and regu-
lators would be more interested in this survey than those that focus only on local
markets. Facilities serving local markets are less likely to care about the mission of
the research or to know their standing against biotech firms in other countries that
are not their competitors. This is particularly true of small and medium sized firms
and firms in emerging markets. Emerging markets serve huge populations and con-
tain many biologics firms that serve only the local population. Differences in local
regulatory policy, IP laws and customers in emerging markets are more likely to be
reflected in the organization of these facilities. In contrast, facilities that serve both
local and global markets would need to adhere to FDA or EMA standards and in-
spections. Thus, the survey may be biased toward global or more forward looking
firms, especially in emerging markets.
Concerns of safety and quality - Facilities and manufacturers exist that are con-
cerned about economic gains above risk for human health and safety. Many cases
of counterfeiting, fraud and intentional use of substandard materials and processes
have been reported by the FDA in their inspections [11]. Such facilities are unlikely
to be interested in the study on global approaches to safety and quality. The is-
sues of quality are likely to be underreported in a study which relies on voluntary
participation.
The survey was launched in April 2011. By 14th June 2011, 14 facilities across
the world had responded completely to the survey and responded to product-specific
questions for 31 products. Many more facilities had accessed the survey and were in
various stages of completion. The respondents in the analysis include some of the
largest and well known biopharma firms in the world and many smaller, lesser-known
facilities. At the time of writing of this thesis, the survey was still online.
In the present analysis, I use data from 14 facilities across North America, Europe
and Asia. This number of facilities represents small fraction of the total number of
facilities in the world. The data also does not represent facilities in South America
which is also an increasingly large producer of biotherapeutic products. Due to the
small sample size it may not be representative of the global population. As more data
is collected, it would be useful to revisit these analyses and test for statistical sig-
nificance.The analysis can be used to obtain empirical evidence, directional insights,
recognize patterns, and highlight key issues for further investigation.
Chapter 3
Microbial Manufacturing
Landscape
Figure 3-1: Growth of recombinant therapeutic products by host-cell type
- The number of microbial therapeutic products has increased exponentially. The
highest number of biotherapeutic products are made in microbial systems.
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Microbial biotherapeutics were the first recombinant products made commercially.
These products are still on the market today. Microbial manufacturing has grown
tremendously since then. [Figure 3-1] shows the exponential growth of recombinant
microbial therapeutic products since the early 80's. Microbial systems are one of the
most popular biomanufacturing hosts. The robust cellular structure of bacteria and
yeast make them amenable to culturing. Microbial cell lines tend to be stable and
the manufacturing processes are less complex than mammalian systems.
In this chapter, I attempt to paint in broad strokes, a picture of microbial bioman-
ufacturing today to understand:
o Where are the main microbial manufacturing facilities in the world ?
o Where are the newer facilities being added?
o Where is the newer capacity being added and by whom?
o What are the major trends microbial manufacturing that are of interest to in-
dustry leaders?
I will begin by studying global trends in biomanufacturing volume by continent.
The analysis will then proceed to increase in granularity by looking at individual
continents. Volume of manufacturing informs only one aspect of biomanufacturing.
In order to get a better understanding of the industry we will look at the trends in
contract manufacturing as well as clinical manufacturing by region. Compared to
product companies, contract manufacturing firms need to focus on low cost man-
ufacturing for profitability. Their presence indicates a vertical specialization that
is emerging in some parts of the industry. Clinical manufacturing involves smaller
volumes of product but is critical step in product and process development in bioman-
ufacturing. Clinical manufacturing is a good indicator of the innovative capacity of
a region and also a critical building block in the development of a robust foundation
for future commercial manufacturing capability for a firm. Following the region wise
analysis we will look at the top 10 countries in this industry - both by volume as well
as by number of facility.
In order to provide context to the data, I followed up the quantitative analysis
with qualitative interviews with leaders in microbial manufacturing in US, UK and
India. In [Section 3.3], I will discuss trends that emerged from the discussions with
industry experts.
3.1 Trends in overall global manufacturing capac-
ity by region
[Figure 3-2 and 3-5] track biomanufacturing investments from 2002 projected to
2013. A number of observations can be made from these graphs.
3.1.1 Trends in global and regional volume
While growth in manufacturing volumes has been more or less stable for microbial
products for most of this decade, it is projected to level off in North America and
Europe by 2010. [Figure 3-2] These trends are primarily due to productivity gains
in the industry.
From [Figure 3-2] and [Figure 3-5] we see that Europe commands almost 50%
of the world capacity by volume (commercial + clinical). This is in contrast to the
mammalian study of biomanufacturing investments where US was a global leader in
mammalian biomanufacturing capacity. [25]
3.1.2 Emergence of Asia
Another interesting trend that can be observed from these charts is is the steady
growth of capacity in Asia over the past seven years. The database is particularly
weak in its estimation of Asian facilities so it is likely the the actual capacity in Asia
is higher than that depicted in the graph. In order to gain a better understanding of
Asian manufacturing I conducted interviews with contract manufacturing firms that
owned facilities in Asia, large pharmaceutical companies that collaborate with teams
in Asia and indigenous product companies in Asia.
The increase in biomanufacturing capacity in Asia can be explained by several fac-
tors. First, a number of Asian countries are targeting the biomanufacturing industry
Figure 3-2: Global trends in microbial manufacturing capacity ( commercial
volume)
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Figure 3-3: Global trends in microbial manufacturing capacity ( clinical
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as a growth industry and thus have made a concerted effort this decade to grow and
develop capacity. Malaysia, India and China are prime examples of this. Many firms
in these locations previously served local markets. They are looking to expand to
newer markets across the world using a wide variety of strategies. Some governments
offer tax benefits to firms that set up operations (Malaysia) or use other means to
attract foreign investment (China and India). Firms in Asia are developing contract
manufacturing capacity to offer the option of low-cost manufacturing to those that
do not want to set up their own operations (India).
Secondly, the possibility of low-cost manufacture has also driven collaborations
between large, well established pharmaceutical firms to acquire and develop capacity
in Asia as a strategy to enter these markets. Asia is particularly attractive for the
production of microbial biotech products. Microbial biotech products have smaller
margins than mammalian products. There is more pressure on margins thus pushing
manufacturers to seek low cost manufacturing locations. Many of these acquisitions
have been driven by generics and small molecules in the past. However, new collab-
orations over biosimilars are emerging that are likely to drive further growth in this
area. Amongst the prominent collaborations include the Biocon/Pfizer partnership
for human insulin and analogs. Daiichi Sankyo's acquisition of Ranbaxy in November
2008 was also driven in part by Ranbaxy's biosimilar capabilities. Biosimilar versions
of 2 microbial biologic drugs (recombinant human growth hormone and filgrastim)
already exist in the European market.
The growth in Asia is being driven by CMOs. Only 3 of the 19 facilities in Asia
are product companies. Of the rest of the 16 firms, 5 are exclusively contract manu-
facturing organizations. A majority of the firms in Asia (11 of 19) do both product
manufacture as well as contract manufacture (mostly clinical). These firms are using
contract manufacturing as a foothold to gain entry into international markets them-
selves. Contract manufacturing in general is playing a large role globally as we will
see in the coming sections.
3.1.3 Analysis by number of facilities
Total volume of capacity is one way to measure the presence and concentration of the
industry by continent. However, manufacturing volumes in microbial facilities vary
widely. Of the 86 clinical facilities, only 2 facilities had capacities larger than 50001.
Clinical capacity, which denotes important innovative capacity of a region, accounts
for only 10% of the total global volume. [Table 3.1.3] shows most microbial facilities
have capacity than 50001 ( clinical + commercial). Less than 15% of all reactors
command 80% of the total global volume.
Table 3.1: Number of microbial facilities by size
# of Facilities
Region Total >10kl 5kl-10kl < 5kl
Europe 61 13 6 42
North America 59 6 2 51
Asia 22 2 2 18
In addition, due to the huge market for the product, insulin manufacturing facil-
ities have a capacity of 60,0001 or more. Insulin manufacture thus dwarfs any other
microbial product when analyzed by volume. Looking at the number of facilities will
help provide some more context to microbial biomanufacturing.
Anlayzing data by volume [Figure 3-2 and 3-5] show Europe to be leading in
global manufacturing capacity. More than a third of this volume is contributed by
3 large insulin facilities in Germany, Denmark and Sweden. The number of large
facilities in Europe are much more than in USA. These large facilities are significant
investments in both continents that will not easily be moved or made obsolete. Most
of these facilities were set up before 2002 where the database begins. These 'sticky'
assets that were established more than a decade ago play a large role in the prominence
of microbial manufacturing in Europe. With recent advances in titres, not too many
new facilities are of the same size. Only 2 new facilities larger than 10kl have been
planned in the future. Both these planned facilities will be for contract manufacture.
See Appendix A for a list of all facilities more than 10kl.
If we look at the number of facilities, US and Europe are comparable with 61 and
59 facilities respectively [Table 3.2]. US has a larger share of clinical facilities than
Europe indicating innovative activity. Asia has less than half the number of clinical
facilities compared to the US but they form a larger share of the total facilities in
Asia. Many of these facilities are contract manufacturing facilities.
Table 3.2: Share of clinical facilities by region
# of Facilities
Region Total Clinical Commercial % Clinical
Europe 61 33 28 54%
North America 59 38 21 64%
Asia 22 15 7 68%
3.2 Top 10 Regions in Microbial Manufacturing
Figure 3-4: Top 10 regions in microbial biomanufacturing (by volume)
Top Microbial Manufacturing Regions (by Volume)
[Table 3-4] increases the granularity of the analysis to look at the top 10 nations
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other nations in terms of both manufacturing volume and number of facilities. This
highlights the role the US has always played as a pioneer and leader in the industry
since its inception. The large volume of insulin facilities plays a significant role in
this ranking as we see in [Figure 3-4]. Following the US (2 insulin facilities) in
microbial manufacturing volume are Sweden, Denmark, India and Germany. Apart
from Denmark, all the other locations also have a large presence of other facilities
[See Table 3.3].
The US also leads the pack in number of facilities by a large margin. It is followed
by a trail of countries with less than one fourth the number and less than half the
volume of US facilities. A large number of the facilities in each of these regions are
clinical facilities which form the foundation of innovation and process development in
the biomanufacturing industry.
Table 3.3: Top 10 Biomanufacturing Locations by Volume - US leads the list
by a large margin. India is the only Asian location. All others are European.
Country Volume Total # of Facilities Clinical % CMO* % Clinical
USA 233,365 53 33 64% 62%
Sweden 92,470 6 2 33% 33%
Denmark 83,000 2 1 50% 50%
India 76,245 13 11 100% 85%
Italy 73,300 3 2 67% 67%
Austria 71,500 7 3 100% 43%
Germany 66,870 11 6 82% 55%
UK 50,775 12 9 92% 75%
Switzerland 34,250 4 2 75% 50%
Netherlands 23,950 5 1 100% 0%
*Includes all facilities that do contract manufacturing (dedicated CMOs and product com-
panies with CMO operations)
A 45,0001 contract manufacturing facility has been planned in Malaysia. Since this volume
has not been realized yet, Malaysia was not included in this list.
Looking at the manufacturing type gives us some insight into the nature of man-
ufacturing activity in these regions. In [Table 3.3], we see that a large majority of
the top 10 facilities are involved in some form of contract manufacture (include ded-
icated contract manufacturers and firms that manufacture their own products and
also contract out a part of their capacity). Contract manufacture is seen to dominate
amongst facilities in the top 10 nations due to emergence of new CMO organizations
and also due to consolidation of the industry and excess capacity in firms that were
using a facility to manufacture their own product. [See discussion in Section 3.3.2]
3.2.1 Insulin
It is interesting to observe that the global market for insulin is served by 5 locations in
the world alone. Only one of these 5 locations is in Asia, even though Asia is projected
to have the highest growth rate of diabetes patients in the world. In the US, insulin is
manufactured in the Midwest and Puerto Rico. As emerging markets grow, it would
be useful to observe how manufacturers in these higher cost locations compete with
manufacturers in location like India and China which are already serving the local
market at a fraction of the cost. Partnerships between Pfizer and Biocon over insulin
have already emerged indicating that many large pharma, perhaps, intend to shift
their manufacture to low cost locations to compete with low cost manufacturers.
To add to this, in the coming years more clarity in biosimilar regulation is likely.
If this happens, as is the case with the human growth hormone, biosimilar manufac-
turers are likely flood European and Asian markets with low cost products. Thus
manufacturers in US and EU will lose the advantage that they claim to have. In the
words of Friedman "the playing field will be leveled' and facilities no longer have a
home advantage and will not be competing for their respective regional / developed
markets / emerging markets. Instead, the battle will be for global markets and fa-
cilities will be forced to be competitive across the world. Insulin is a much simpler
product than other microbial and mammalian products existing in the world today.
The market for insulin has also been differentiated by newer delivery methods ( pens
/ vials and in the future perhaps oral insulin) that aim at patient comfort. In addition
to product differentiation, factors like regulatory stringency and technological com-
plexity, market differentiation and size of manufacture may impact the speed with
which low-cost products enter the market.
3.3 Discussion of the main trends
Following the quantitative analysis of the data, I conducted qualitative interviews
with leaders in the industry as well as focus groups. A number of trends emerged from
the quantitative analysis and subsequent qualitative interviews that are interesting
to observe :
3.3.1 Overall manufacturing capacity is reaching a steady
state
The overall capacity that serves US and EU markets seems to have been stable over the
past few years. Due to simpler processes, developments in technology have been able
to improve yields of microbial products to a greater extent than any other biotech
manufacture type. As a result, capacity utilization of microbial facilities has been
dropping. Based on industry reports, capacity utilization has dropped by 13% for
microbial fermentation over 2004 -2008 [2]
Upstream production efficiencies continue to generate higher product yields. So
far, improvements in upstream yields have been enough to meet any increase in de-
mand for microbial capacity. The need for the additional capacity is decreasing
as many large biopharmaceutical companies are using the extra capacity they have
acquired for contract manufacturing e.g. BI (12,000 litre capacity reactors), Novar-
tis/Sandoz (40,0001 and 6,0001), and Merck/Diosynth (14,000 and 7,5001).
However, there are certain segments of the industry, including larger biopharma-
ceutical developers that continue to experience capacity constraints. These are mainly
contract manufacturing organizations (CMOs). Over the past decade, CMOs have
been the main class of manufacturers to set up new facilities [Table 3.4]. All other seg-
ments of manufacturers (product manufacturers and manufacturers that contracted
out some of their own capacity) did not face any capacity constraints. This trend
Table 3.4: Increase in number of
the largest number of new facilities.
facilities by firm type - CMOs have set up
# of Facilities
Clinical Commercial
2005 2013 2005 2013
Both 17 21 10 10
CMO 45 60 16 22
Product Company 10 11 24 29
3-5: Increase in number of facilities(clinical+commercial) by firm
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for contract manufacturers is likely to increase in the coming years and will impact
the biomanufacturing landscape. Most contract manufacturers rely on their exper-
tise and ability manufacture at extremely low costs in order to be profitable. Many
CMOs choose to locate themselves in locations that are either low cost or provide tax
rebates to maintain margins. As the industry depends more on contract manufactur-
ing we can expect the contract manufacturing industry to play a role in pushing the
industry away from its R&D centers and clusters. Whether or not they will succeed
will depend on the state of technology and complexity and regulatory policies at the
time. [see Section 3.3.2]
3.3.2 Growth of contract manufacturing
In spite of dropping capacity utilization in the industry, there is expected to be a a
rise in contract manufacturing organizations. Contract manufacturing organizations
are the only segment in the industry that is facing capacity constraints. This may
be attributed to the increasing risk associated with biomanufacturing. The FDA in
particular has been increasing the requirements for drug approval. At same time, the
approval times have become longer. The business of biotechnology is now risky and
uncertain due to complexity of technology as well as well as regulatory uncertainty.
According to Di Masi, probability of Phase 3 approval is now as low at 26% for
biotech firms on average. For a small biotech firm, this means that if they set up
manufacturing for a new biotech drug, there is a 74% probability that the facility will
not be used at all. As the costs of drug developments increase, more and more small
biotech firms will find it difficult to set up their own manufacturing operations. Most
small biotech firms are now choosing to either license to large pharmaceutical firms
or contract out to CMOs.
In addition to the sunk cost of setting up a facility, the firms also have to bear
the risk of manufacturing and FDA approval that they have little or no experience
with. This is where CMOs offer a unique value proposition. Most CMOs offer to
manufacture small quantities of a product in early stages of development and bear the
risk of approval. In return, small biotech firms pay manufacturers for manufacture of
the drug before approval and also promise to assign the contract for commercial scale
manufacture to the CMO. This provides a win-win situation for both small biotech
as well as CMOs. CMOs develop expertise in manufacturing and regulatory approval
while small biotech firms can focus their attention and efforts on drug development.
3.3.3 Downstream processing costs
With improvements in upstream titres, there is additional pressure on building more
efficient and cost effective downstream purification systems. Downstream purification
is not easily scalable and is currently the main critical bottleneck. All interviewees
across both mammalian and microbial manufacture identified improving downstream
performance is an area of keen interest. Microbial manufacturing in its upstream
processes involves low cost media and high yields. As product yields become higher,
purification downstream becomes more costly. As a result, downstream purification
for microbial products contributes to almost 60% of the cost while upstream accounts
for 40%.
In contrast, in mammalian manufacture, upstream processes involve more expen-
sive and complex media, lower titres and longer times. Downstream processes for
mammalian products are more complex than their microbial counterparts, but less
expensive than upstream mammalian manufacture. Overall they account for almost
40% of of the total costs while upstream manufacture forms the remaining 60%. 1
3.3.4 Upstream innovation focus varies by firm
All firms interviewed were aware of different challenges in upstream innovation in
microbial and mammalian systems. However, within the firm the focus of innovation
varied. Some firms with established expertise in a mammalian system did very little
innovation upstream on microbial platforms. Other large firms had dedicated groups
that explored possibilities of using diverse platforms (mammalian/microbial/others)
for the same product. Manufacturing concerns were factored in early on in the devel-
'Source: from MTC interviews
opment of the product and some firms had established team structures and processes
that would allow incorporation of learning from manufacturing teams in upstream
innovation e.g. reagents, processes, cell lines. Scale up of microbial systems and
manufacturing processes did not come up as a major issue.
Many firms were looking at better disposable reactors that that can be used for
both mammalian and microbial manufacture. Some CMOs also mentioned how using
the same facility for mammalian and microbial based products provides significant
cost savings in time, space and infrastructure. Co-location of manufacturing units
also allows shared use of personnel and expertise. This promotes increasing interest
and R&D in the use of disposable reactors, especially in contract manufacturing.
3.3.5 Offshoring and outsourcing
Most firms that were interviewed suggested that there was constantly a push to
decrease costs. This is even more applicable in microbial manufacturing given the
narrow margins of microbial biopharma. There is increasing pressure on biopharma-
ceutical firms to reduce the cost of health care which is further encouraging firms
to relocate manufacturing to offshore low cost locations. Tax benefit locations like
Ireland , Malaysia and India provide attractive options to microbial biopharmaceu-
tical manufacturers. However, not too many firms have taken this option as we saw
in [Section 3.2]. India is the only Asian location to feature in the top 10 regions
for biomanufacturing. Many firms prefer to the test waters through contract manu-
facturing and collaborations. Thus in new locations that are away from traditional
centers of knowledge in the US and EU are likely to either be involved in a different
kind of manufacturing activity or perform the same kind of manufacture differently.
In order to further investigate this, we must drill deeper into the organization and
function of the facilities themselves in order to uncover the difference in the nature
of manufacturing activity. We proceed to this through a global facility level survey
that will be discussed in the next chapter.
Chapter 4
Nature of Manufacturing Activity
by Region
In the previous section we saw a high level snapshot of the global microbial bioman-
ufacturing industry today. In this section we delve deeper to understand the finer
aspects of biomanufacturing using a global survey of the industry conducted by the
Center for Biomedical Innovation. Despite imperfections in the data, the current
dataset demonstrates several key patterns in the globalizing industry. In this section
we study differences in the nature of manufacturing activity among various regions.
Manufacturing facilities are difficult to compare given the wide variations in the type
and complexity of products that they manufacture. In this chapter we try to compare
manufacturing activity across regions by:
The scope of operations ('how much') - Number of products, markets and regula-
tors served by facilities.
The type of operations ('what kind') - Efficiency of manufacture, complexity of
products and processes, focus on research vs commercial manufacture etc.
4.1 Scope of operations
4.1.1 Products, markets and regulators
Understanding the products, markets and regulators served by a facility gives us a
good understanding of the scope of its operations. A facility that serves more markets
and regulators is likely to be 'world class' in the sense that it has been approved by
multiple regulators and its product serves patients around the world. Though all man-
ufacturing regulations are based on cGMPs (current good manufacturing practices),
regulatory authorities around the world have different requirements and procedures
for approval. Serving many markets and regulators also indicates that facilities ful-
fill a superset of requirements and have the expertise needed to maintain a level of
quality and safety that is acceptable to most regulatory authorities.
Table 4.1 summarizes the average number of markets and regulators served per
facility in each region. The markets included US, EU, Canada, Japan, South Amer-
ica, Asia, Middle East and others. Regulating authorities include FDA - CDER, FDA
- CBER, EMA and relevant authorities in Canada, Brazil, Japan, China, India, Aus-
tralia, Gulf Council and South Korea. Only 1 of the 4 Asian facilities that responded
served an international market; the other 3 served only domestic markets. In two
cases, facilities that were serving markets outside US and EU only interacted with
regulators from FDA and EMA respectively. This is because the developing nations
that they serve recognize standards by the FDA and the EMA and allow facilities
approved by these organizations to serve their markets.
If we look at the average number of biologics per facility, we see that US has the
highest average number of products per facility (12.2) while Asian facilities have an
average of just more than 3 products [Table 4.1].
The difference between the number of products manufactured by Asian and US/
EU facilities may be due to many reasons - clinical operations, less complex opera-
tions, different type of firms or larger facilities. We discuss each of these below.
More clinical operations
Some of the American and EU facilities also support clinical processes while Asian fa-
Table 4.1: Products, markets and regulators served by facilities by region -
US leads in all three parameters, followed by Europe.
Facility Avg # of Markets Avg # of Regulators Avg # of Biologics
Region served by each fa- interacted with per manufactured per fa-
cility facility cility
Asia 2 2 3.25
EU 4.2 2.6 6.75
USA 4.6 4.8 12.2
The markets included US, EU, Canada, Japan, South America, Asia, Middle East and Others.
*Regulating authorities include US - FDA - CDER, US - FDA - CBER, EMA and relevant author-
ities in the following regions: Canada, Brazil, Japan, China, India, Australia, Gulf Council, South
Korea
cilities support only commercial scale manufacture. As clinical development requires
lower volumes, it is possible for facilities to support many products. Clinical oper-
ations indicate greater innovative activity in a facility. However, this is beyond the
scope of the survey as it did not capture whether the manufacture was at a commercial
or clinical scale for each of the products.
Type of firm - Contract Manufacturing Organization or Product Company
Firms that perform contract manufacturing, because of their business model, usually
support more products within the same facility. In this dataset, the number of prod-
ucts manufactured by CMOs1 varied between 4 - 25 products. Even when comparing
across CMOs in this limited dataset, the ones in the US supported more products
than those in EU or Asia.
Larger facilities with more employees
Another reason that explains how some facilities manufacture more products is the
number of employees employed in the facility. However, we see no correlation between
the two variables, which may indicate that the US facilities are more productive. [See
Appendix B-2 for correlation] We discuss this in detail in the next section.
Simpler operations for more products
The total number of products supported by a facility is also likely to depend on the
kind of process it supports. For example, upstream cell culture processes with large
'defined as facilities <50% capacity used for manufacturing
volumes of cultures require weeks for a batch to run through. In contrast, fill/finish
and product packaging operations can be completed for a batch within a few days.
Even within cell culture, differences in complexity of the culture or the fermentation
operation may limit the number of the products that can be manufactured (typically,
microbial cell fermentation processes take less time than mammalian operations).
Facilities that perform simpler processes have more time to support multiple products
within the same facility; this may be responsible for the difference in number of
products manufactured by the facility. We will see in [Section 4.4] why this is not
true, and how US/EU facilities support more complex processes compared to Asian
facilities.
Manufacturing a large number of products in a facility is a challenge. A large
number of products in the same facility increases chances of contamination and re-
quires better control over processes to maintain quality and safety. The risk and cost
of decontaminating a facility is very high. Contamination or quality issues may result
in loss of revenue or market and sometimes even death of patients. However, most
facilities in the survey manufactured more than one product in the facility and, based
on interviews, it is most likely to increase because of the reasons discussed below.
4.2 Productivity of facilities by region
When trying to characterize the manufacturing activity in a facility, efficiency and
productivity of the employees can help us understand whether the facility is doing
more with fewer or similar resources.
In this section, we will try to compare facilities that are making more products or
serving more markets with 2 of the resources that they have - manufacturing capacity
and the number of employees.
4.2.1 Utilization of capacity by region
Manufacturing more products in a facility may be driven by the need to utilize excess
capacity. With improvements in upstream yields, it is possible to manufacture more
product per volume. The desired demand is then met by running fewer batches which
leads to spare manufacturing capacity once the product run is complete.
Manufacturing sites which produce a larger number of biologics were associated
with the highest capacity utilization. [Table 4.2]
Table 4.2: Capacity utilization and number of biologics manufactured - The
table has been divided into 3 sections - High, Medium and Low Performers. 3 of 4
facilities in the bottom segment were in Asia.
Facility Perfusion Batch Utiliza- Number of Bi- CMO* Large
Utilization tion ologics Pharma
Facilityl *** 61% to 70% 25 Yes
Facility2 *** 81% to 90% 25 Yes
Facility3 26% to 50% 71% to 80% 12 Yes
Facility4 26% to 50% 26% to 50% 8 Yes
Facility5 *** 51% to 60% 5 Yes
Facility6 < 25% 26% to 50% 5 Yes
Facility7 < 25% 51% to 60% 4
Facility8 < 25% 71% to 80% 4 Yes
Facility9 71% to 80% < 25% 4
FacilitylO 91% to 100% 91% to 100% 3
Facilityll * K 25% 3
Facility12 * < 25% 2
Facility13 * 1
Facility14 * < 25% 1
*Facilities where more than 50% of capacity is used for contract manufacture
In [Table 4.2] we see that the facilities can be divided segmented into 3 types
based on the number of products and their capacity utilization :-
1. High Performers (large number of product and a high capacity utilization) -
There are 3 facilities in this category that manufacture more than 12 products
and have a capacity utilization higher than 60%.
2. Medium (3 or more products or a very high capacity utilization) - Most facil-
ities fall into this category. Their capacity utilization varies between 26% to
100% and number of products ranges between 3 - 8 products. In this group,
facilities with a large number of products had a lower capacity utilization (26-
60%) while the facilities with low number of products had a relatively higher
capacity utilization (51-100%).
3. Low Performers (few products and low capacity utilization) - These facilities
are the least efficient in terms of utilizing capacity. The facilities are less than
a quarter of their capacity and manufacture only 1- 3 products.
Maintaining excess capacity in US and EU facilities is a greater burden due to
the fixed cost in setting up a facility as well as the high cost of maintaining a facility
and its GMP status. Facilities in EU and US have more reason to manufacture more
products within the same facility. 2 of the 3 facilities in the top segment are US
facilities.
In contrast, the cost of setting up a new facility or acquiring an existing facility is
relatively lower in locations like Asia [28] which forms a majority of the last segment.
3 of the 4 facilities in the last segment were in Asia. Even though these facilities
have excess capacity, they are not using it to manufacture more products. This hints
to either an inefficient process or the lack of incentive to utilize full capacity or a
combination of both. [Appendix B] shows a weak correlation between the number of
biologics manufactured in the facility and capacity utilization.
4.2.2 Productivity of workforce
There was no correlation between the number of employees and the number of prod-
ucts manufactured in a facility. This implies that facilities that manufactured more
products were doing so without adding more employees. Employees in US/EU fa-
cilites perform more operations for more products than their Asian counterparts with
fewer products and markets. [See Appendix B-2 for details.]
US/EU facilities can possibly be considered more productive than Asian facilities.
However, this may just be due to the lack of expertise in Asian facilities to mamange
more products. Studies show that there are gaps in expertise in workforce in some
parts of the Asian biopharmaceutical industry [27, 33]; expertise usually plays a large
role in the efficiency and productivity and growth of the industry. [25, 18, 15, 14]
4.3 Accumulation of expertise
In [Section 4.1], we saw how a maintaining a large scope of operations in a facility
is a challenge that not all facilities or regions are able to support. In this section
I discuss how the ability to perfrom more operations may be linked to its expertise
acquired over time.
Older facilities have more employees, make more products, serve more markets on
average than younger facilities
In [Table 4.3] we see that facilities older than 15 years on average, serve more
than twice the number of markets and interact with thrice the number of regulators
than younger facilities.
Older facilities also employed more people [Figure 4-1] and manufactured more
products [Table 4.3] [See Appendix B-4 for details]. One could argue that facilities
in Asia, due to cheap labor, could possibly employ more workers. However, even in
the small sample used here, we see large facilities in Asia,the US and the EU with
more than 500 employees. Each of these facilities is more than 20 years old. This
indicates that facilities progressively grow with success of a product and serve more
products with time.
Number of products and number of employees had some correlation with the age
of the facility they were not correlated to each other. [Appendix B-2]. Thus facilities
appear to grow in size not only because they are making more products but something
else that is added over time - investment in R&D and expertise. There may also be
knowledge that is acquired over time that allow facilities to build on their efficiencies
and allow them to successfully manufacture more products with time.
Table 4.3: Number of markets and regulators served by older facilities -
Facilities older than 15 years serve more markets and manufacture more products
than younger facilities. With time younger facilities may be expected to develop
expertise in their processes and increase the services they offer - in terms of markets
served or products manufactured.
Facility Age (in # of # of # of Avg # Avg
yrs) Emps Mkts Regu- of Mkts Regu-
Served lators a lators
2 4
Facilityl* 55 > 500 5 4
Facility2 29 101 to 500 7 11
Facility3 28 > 500 5 3
Facility4 21 > 500 7 8 5.7 5.2
Facility5 17 51 to 100 4 4
Facility6 16 Less than 6 1
50
Facility7 13 51 to 100 1 1
Facility8 12 Less than 1 2
50
Facility9 11 Less than 1 2 2.3 1.9
50
Facilityl0 10 51 to 100 7 4
Facility11 9 101 to 500 4 1
Facilityl2 6 101 to 500 1 2
Facility13 2 Less than 1 0
50
Facilityl4 2 Less than 2 3
50
*This facility is an outlier due to its age. It is likely to have been manufacturing non-
recombinant proteins from animals before the 1980s when recombinant technology was
introduced. It has been upgraded over time. Excluding this facility does not change the
overall result.
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Figure 4-1: Number of employees vs Age of facility- Correlation between age of
a facility and number of employees indicates clustering of expertise in a facility with
time. Older facilities serve more markets and products. See [Table 4.3)
]
Studies show that newer entrants (new clusters) into the biotech arena need to
'catch up' to clusters and firms that have existed in this industry for more time. [17]
From [Table 4.3] we may be able to deduce that younger facilities are not choosing
to manufacture fewer products for fewer markets. Instead, they need to first develop
expertise with a few products. Over time, they can use the revenue generated to
perform more R&D and build their expertise allowing the facility to grow in size and
scope.
Learning acquired over time may not be the only reason younger facilities are
doing less. Another factor that can play into scope of operations that a new facility
can support is the time required for approval. Approvals by regulatory authorities
are slow processes and firms typically attempt to get approval from one agency first.
This allows them to begin earning revenue sooner rather than waiting for approval
from all authorities for many markets and then beginning production. It would be
useful to study the trends in growth of large facilities to be able to compare the rate
at which these facilities acquire expertise and build on their learning. This is however,
beyond the scope of this study.
4.3.1 Clustering of facilities in US and EU
Another possible reason for older facilities having more products is due to clus-
tering. In the MTC interviews, different firms provided different reasons for the
clustering around established centers like Boston. Interviews with facilities around
Massachusetts revealed that for some manufacturers, one of the factors determining
the location of the facility was its proximity to pre-existing well established facilities
owned by the same organization 5 . The proximity would allow them to share resources-
both technical and administrative across these facilities. This was a common theme
across well established biopharma firms and contract manufacturers. Around Mas-
sachusetts, most of the large and small biotech firms focused heavily on upstream
research and process improvement. Most firms have clinical capacity and are not
manufacturing on a commercial scale which might have some influence on their views
on the importance of cluster for manufacturing.
Some facilities are also trying to share resources across both mammalian and
microbial products. Since both these processes vary widely, traditionally a facility is
defined by its manufacture type. However, facilities are increasingly looking to create
'hybrid facilities that support both these processes. If that were to happen, we would
see an even higher number of biologics in a facility. Some CMOs also mentioned how
using the same facility for mammalian and microbial products provides significant
cost savings in time, space and infrastructure. Co-location of manufacturing units
also allows shared use of personnel and expertise. This also explains the increasing
interest and R&D in the use of disposable reactors.
When it came to choosing locations, different factors are favored by small and large
firms. In the interviews conducted around Cambridge and Massachusetts, most small
biopharma were spun off from a collaboration with MIT and other academic centers.
As a result, they mainly set up or expanded existing R&D centers due to proximity
to centers of innovation and collaboration. Many of these firms found it easier to
get experienced hires for locations in Massachusetts due to the vibrant cluster. Most
of these companies believe that locating elsewhere can significantly increase project
'Reactor sizes and facilities at the manufacturing site were primary factors driving the decisions.
management, general management, rejection rates, logistics, and distribution costs.
As a result, when they move out of their pilot phase, they usually choose to keep
their manufacturing locations close to the R&D locations. Increasingly, due to the
risk and cost of setting up manufacture, many facilities are choosing to contract out
their operations.
Large biopharmaceutical firms have the infrastructure for outsourcing and have
well established organizational processes that would help teams collaborate over long
distances. Some of the interviewees in large firms did not feel that the cluster effect
was crucial to their success in manufacturing but was a nice 'bonus'. Their primary
reason to be located in Massachusetts was the access to expertise and academic re-
search proximity.
Thus the simpler and more stable product, the likely it is to be moved to a
new location. 6 For example, a large pharmaceutical firm with a mature microbial
based product and very stable processes was moved from its old facility in Europe to a
facility in Massachusetts in a consolidation effort since it was deemed easier and lower
risk than to move a complex product to any low cost location. The number of biologics
manufactured, the global markets served by the facilities, the regulators and numbers
of employees in a facility indicate increased clustering of manufacturing facilities and
consolidation of expertise in EU and USA. Thus firms prefer to manufacture certain
products in EU and USA instead of moving that manufacture to a low cost location.
In summary, these graphs, tables as well as quaitative interviews suggest that
older facilities may have an edge over newer facilities when it comes to availability of
experienced employees and other resources which allows them to manufacture more
products for more markets and also be more efficient.
6 MTC Interviews and anecdotal evidence
4.4 Organization and processes in manufacturing
facilities by region
In the previous section we looked at the number of operations in order to understand
the manufacturing activity in a facility. However, the number of operations tell us
only half the story. It is possible that a facility performs a large number of simpler
operations while others try to perform a smaller number of very complex operations.
In order to better understand the difference in manufacturing activities in different
regions, we look in further detail at the operations of the facility in different loca-
tions. The next section analyzes how different facilities approach their processes,
organization and the parameters of safety and quality differently.
4.4.1 Uniform organization across functions
Table 4.4: Percentage of total employees in key roles by region 8 The distribu-
tion of employees is more or less uniform. US and EU facilities have more employees
(over 30%) in QA+QC functions compared to Asia where more employees are involved
in manufacturing operations.
Function
Region Quality Assur- Quality Engg. Manufac- Technical
ance Control Support turing
Services
USA 15% 16% 9% 41% 19%
EU 9% 23% 7% 44% 17%
Asia 11% 16% 8% 48% 17%
All Regions 12% 17% 8% 45% 17%
Table 4.4 shows the distribution of employees across 5 major functions. Organi-
zation of the facilities is more or less uniform across all locations with some minor
variations. Based on the preliminary data, Asia has marginally more people involved
in the manufacturing operations. US and EU had a slightly greater share of em-
ployees (over 30%) involved in QA and QC while Asian facilities employed only 27%
of their employees in QA and QC operations. There is too little data to test if the
variations across regions are statistically significant. Fewer employees in QA and QC
could indicate either a lax approach to quality or that the manufacturing operations
in Asian facilities are simpler, well understood and easily controlled as compared to
those in US and EU facilities.
4.4.2 Comparison of type of processes by region
Looking at the types of manufacturing processes help us further understand the func-
tions of the facility. The types of processes in a manufacturing facility vary widely in
complexity and value. [Figure 4-2] shows that 89% of European products and 80% of
US products involve cell culture while only 29% of the Asian products manufactured
in facilities are supported by the same processes.
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Figure 4-2: Type of processes supported for products in a facility by region
- US/EU facilities specialize in a few processes (cell culture/purification) compared
to a broad spectrum of facilities in Asian facilities. Asian facilities perform simpler
processes ( fermentation over cell culture) and low value downstream operations like
fill/finish and product packaging.
Type of processes supported vary in type and complexity
As we analyze the types of operations, we see that none of the US or European
facilities performed any sort of product packaging (fill/finish), which is a relatively low
value process compared to cell culture. It also requires less expertise as the product
has already been manufactured and purified. All of the Asian facilities that have
responded to the survey support product packaging processes. This may be because
Asian facilities are able to replicate simpler processes at a lower cost.
Asian facilities support a broad spectrum of processes like fermentation, purifica-
tion as well as packaging for a fewer number of products in the facility. This indicates
a more integrated manufacturing with all processes performed in the same location.
In contrast, US/EU facilities specialized in a cell culture and purification for a large
number of products. [See Section 4.1]
There were some US/EU products where cell culture was performed in one facility
but it was not purified at the same location. This explains the disparity in the cell
culture and down stream purification(DSP) for US and EU facilities. This may have
been due to infrastructural limitations when the company was building or expanding
their existing manufacturing facility. For example, if the land in one spot on campus
is only enough to house the fermentation unit, the DSP would have to be housed in
a separate nearby location. This happens to established companies more than new
start-ups. Tanker trucks are used to transfer the harvested broth to another location
on the same campus for DSP. Separation of cell culture from DSP is not a common
practice, but it exists. ' It is also possible that when responding to the survey,
respondents assumed cell culture to include purification. (All cell culture is followed
by purification).
4.4.3 Comparison of cell culture by region
When comparing cell culture processes alone, more Asian products were manufactured
from (microbial) fermentation processes, an older, widely understood technology, in-
stead of (mammalian) cell culture which is relatively newer.
There are exceptions to this. Some well established cell cultures are not more
complicated in operations than microbial systems. A better metric to compare the
complexity of a cell culture / fermentation process or even the overall manufacturing
process of a product is the number of unit operations. We discuss this in the next
section.
9 Discussion and consensus with CBI focus groups and anecdotal evidence
4.5 Complexity of processes by region
4.5.1 Unit Operations - A brief introduction
A unit operation in chemical engineering refers to a step or function in the manufac-
turing process. A process with a large number of unit operations is one that involves
several steps / operations on or with materials to form the final product. Amongst
industry leaders, it was generally agreed that a large number of unit operations is an
indicator of product complexity.
In the survey, the respondents were asked to specify the number of unit opera-
tions in each of the following processes: cell culture, purification and fill/finish. The
numbers of operations in each process were summed up to find the total number
of unit operations for the product in the facility. The total number of unit opera-
tions involved in the manufacture of a product is a good proxy for the complexity
of the overall manufacturing operation. In this section we analyse the overall com-
plexity of the product/process across regions. We also try to control for the kind of
processes a facility supports (upstream vs. downstream) by comparing complexity
across only cell culture and purification across regions. (All regions supported cell
culture (mammalian or microbial) and purification in their facilities. Finally, we try
to control for product type and compare compare the number of unit operations of
mammalian products and microbial products across regions. A total of 27 products
across 9 facilities were studied for this analysis.
4.5.2 Total unit operations (cell culture + purification + fill/
finish)
When looking at a distribution of products across the number of unit operations by
region we see that the most complex process in Asia has only 11 unit operations com-
pared to 13 unit operations in Europe. US products had the highest unit operations
at 19. The median of the distribution of unit operations in Table 4.5 indicate a
higher overall complexity in US and Europe as compared to Asia.
Table 4.5: Median, Max and Min unit operations supported by facilities by
region - US facilities are supporting more more unit operations followed by EU and
finally Asian facilities.
Unit operations ( Cell culture + purification + fill-finish)
Region n Median Max Min
Asia 6 7.5 11 7
EU 9 9 13 7
USA 12 13.5 19 4*
* Does not include fill finish. The minimum unit operations for a facility that did enter
number of fill finish operations was 10.
Differences between the US and Asia facilities are significant at 94% confidence.
The number of data points here is too small to be able to generalize this result on
the general population. [See Appendix A.2]. Nevertheless the pattern displayed here
is significant and highlights an important difference in the nature of manufacturing
activity between regions.
4.5.3 Complexity of upstream processes only (cell culture+
purification)
Table 4.6: Median, Max and Min unit operations supported across cell
culture + purification by region - When controlling for the processes supported,
we see the pattern remain unchanged. US facilities still support products with the
highest numbr of unit operations. The most complex product in Asian facilities is
simpler than those in EU and US.
Unit operations ( Cell culture + purification)
Region n Median Max Min
Asia 6 6.5 9 5
EU 9 9 12 6
USA 12 10 15 4
In [Section 4.4.2], we saw that processes supported by a facility are different. We
try to control for this by comparing the number of unit operations in the cell culture
and purification processes alone. (Only Asian facilities did fill/finish.) Table 4.6
compares the number of unit operations in the cell culture and purification processes
alone. We see that US products still have the most unit operations. The average
number of operations for US products is the highest of the 3 regions. The maximum
number of operations for a product in the US was higher than the corresponding
product in EU followed by Asia.
4.5.4 Complexity by host cell type (mammalian and micro-
bial) by region
Complexity of processes also vary by manufacture type. In [Table 4.8] we compare
only mammalian products across the regions. We still see similar results with US
having the highest average number of unit operations followed by Europe and Asia.
Looking at microbial products alone, we see the pattern remains unchanged with
US facilities having the highest average number of unit operations followed by Asia
[Table 4.7]. No EU facility that responded manufactured microbial products.
Table 4.7: Average unit operations for microbial products by region
Region Culture type n Average
US Microbial 2 16.5
Asia Microbial 4 9
Europe Microbial 0 NA
Table 4.8: Average unit operations for mammalian products by region
Region Culture type n Average
US Mammalian 10 11.8
Asia Mammalian 2 7
Europe Mammalian 9 9.8
It is interesting to note that the average number of unit operations for microbial
products is more than that of mammalian products. This is contrary to the general
perception that microbial processes are simpler than mammalian processes. Discus-
sion with CBI focus groups reveal that this may not always be the case anymore.
With time the number of unit operations between microbial and mammalian pro-
cesses may be comparable. Two reasons can be hypothesized:
1. Process turn around times: At times, since the microbial processes are shorter
in duration, more time is spent in turning the process around than cell culture, and
actually requiring more labor allocation per year.
2. The establishment of standards in mammalian production: A standard process
platforms and configurations of methods like Protein A columns (and other ionic
exchange columns) has streamlined mAb production. Most companies ( in US/EU)
now have a high level of knowledge and experience allowing operations to become
simpler. On a per weight basis, mAb is very low on a cost of goods sold (COGS)
curve compared to other growth factors made by microbial process. In comparison,
some processes making a special protein with E. Coli most likely are customized for
that protein and more complicated; as a result, these processes are not practiced
by other companies in the industry. It is a misconception that making cell culture
product is more complicated and more expensive. 10
This is supported by data in [Table 4.7] and [Table 4.8] where we see micro-
bial products in US facilities with higher unit operations indicating highly innovative
'special proteins' that were described above.
4.5.5 Unit operations as a metric
Analysis of unit operations further strengthens the hypothesis that products in Asian
facilities are indeed less complex than those in EU and US facilities. Even with
increasing financial pressures, the products that firms are comfortable manufacturing
in Asia are simpler and on average face fewer quality issues than products that are
manufactured in the US and EU facilities.
Unit operations can be a useful metric to compare length and complexity of man-
ufacturing operations in bio-manufacturing. Unit operations are understood across
the industry by all persons. They are rooted in engineering principles and do not
10 CBI focus group and anecdotal evidence
vary by regulatory guidelines.
Lack of standards across facilities on how to define a unit operation may create
some confusion in analysis. For example, a purification step may involve filtration
through several columns. Between different filtration steps, the columns have to be
de-salted. Some facilities may include desalting as a separate operation while others
may include it in the filtration process making the number of unit operations reported
by one facility double even though both facilities are performing the same operations.
However, if defined consistently, they can provide deep insight into manufacturing
activity and complexity.
4.5.6 Unit operations and quality issues
There are several implications of supporting a high number of unit operations, the
most important being that an increasingly complex process gets progressively more
difficult to control, leading to quality issues. In the survey, facilities were asked
questions relating to quality issues. This included questions on the percentage of lots
that are rejected, number of of critical deviation and number of unresolved deviations.
As deviations in a biopharmaceutical production facility can have legal implications,
there is considerable reason for facilities to choose to not reveal that information or
under-report it and understandably, many facilities chose not to respond to those
questions.
The percentage of total lots rejected have fewer regulatory implications for the
facility. Lots of product may be rejected because of any inconsistency between batches
that was identified by the quality teams at any time during the operation. In some
cases batches are rejected in case there is any reason for QA to believe that the
final product may not be of consistent quality. In such cases, it would be cheaper
to re-do an entire batch rather than waste time and resources on completing a batch
of product that you woild have to test and discard later. Being able to reproduce
consistent quality product, batch to batch, is a indicator of a well controlled process.
The percentage of total lots of product that are rejected can therefore be used as a
proxy for extent of quality issues faced by the facility. [Figure B-3] shows a correlation
between the number of unit operations and % of Lots Rejected. Fewer % rejected
lots indicate better control over processes to ensure consistency between batches of
manufactured product and thus less likelihood of safety or quality issues. In some
cases, fewer percentage of lots rejected may indicate that QA personnel are not doing
their job correctly and substandard products are entering the market.
4.6 Manufacturing quality issues by region
The number and kind of quality issues faced by a facility are an indicator of the kind
of innovative activity in a facility. The stage at which a quality issue is discovered
defines the robustness of its R&D and process research as well as the efficiency of its
operations. Facilities that catch more issues earlier on in the development process
avoid issues in commercial scale when they are more expensive and time consuming
to correct and also detrimental to the firms image.
In this section we look at the kind of quality issues and the stage at which they
are discovered by region.
4.6.1 Stage at which quality issues are discovered
Of the facilities that responded in [Figure 4-3], most US facilities discover quality
issues for their products in early stages like process research and pilot development.
Fewer US products have quality issues discovered in later stages of the manufacturing
process. In case of Asian and European facilities, we see the opposite trend with fewer
facilities being discovered in earlier stages and a larger number of issues being seen
in full scale production. Discovering quality issues during full scale production is ex-
tremely expensive and sometime detrimental to the facilities standing with regulators
and the general public.
Figure 4-3: Stage at which quality issues are discovered- US facilities discover
most quality issue in early stages of process research and fewer issue in subsequent
stages. Most EU and Asian facilities find few issues early on and more issues in late
stage manufacturing or pilot development.
4.6.2 A difference in approach to manufacturing quality
[Figure 4-3] speaks to the importance of process research in manufacturing. If we look
at quality issues faced by US facilities, we see a large number of products facing issues
in process research. However, in each subsequent stage, the issues drop dramatically
in contrast to EU and Asian facilities. This also highlights a fundamentally different
approach to manufacturing in US facilities that put a lot of focus on robust process
research. The overwhelming share of process research related issues faced by products
in the US indicate that either most of the innovative process research happens first in
the US, following which, the products are manufactured in other parts of the world.
In contrast EU and Asian facilities to little or no process research and as a result, a
greater share of the issues they face are in later stage development and manufacture.
This is consistent with the kind of issues faced by EU and Asian facilities that we see
in the next section.
4.6.3 The kind of quality issues observed
In the survey, respondents were given 4 options for quality issues that were observed
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Contaminations issues, which in the recent past have received a lot of press were
not the major challenge that manufacturers face. These are also likely to be under
reported.
Most US and European manufactured products face issues related to product
variation, impurities and contamination which are all linked to product and process
complexity. Product glycosylation-one of the main challenges of mammalian manu-
facture was the most common issue seen in US facilities. This also confirms that the
main challenge in biomanufacturing is still linked to product and process complexity.
Much of these challenges are being faced by US facilities, where, as we saw in the
previous section, a large part of process research is still located.
EU manufactured products faced issues that were related to commercial manufac-
ture which is possibly where a a greater focus of their operations lie. The difference
betwen EU and US facilities may possibly be due to differing regulatory focus between
the FDA and EMA. However, most facilities in US and EU served both regulators so
this is unlikely to be a differentiating factor. This could also mean EU facilities do a
better job of managing glycosylation issues than US facilities.
More than 40% of the products in Asian facilities face quality issues that lie
outside of the 4 main issues listed in the survey. This may imply that they faced no
issues at all or the issues were not categorized under the options provided. Given the
simpler processes that they support, it is possible that Asian facilities face no issues
in manufacture. In case it is the latter, it would be interesting to follow with the
respective firms with qualitative interviews to understand what kind of issues Asian
facilities face and how they are resolved.
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Chapter 5
Conclusions
This study aims to paint in broad brush strokes a picture of the global microbial
biomanufacturing industry today and then dive deeper to provide finer details about
the complexity of the manufacturing activity in different regions. The idea that
complexity of the technology is a factor that determines location of biomanufacturing
has been around for some time [23, 9, 25, 17]. This study contributed to the existing
literature by using metrics embedded in the biomanufacturing process to support that
hypothesis. In this study, the complexity of biomanufacturing has been defined in
terms of the number of operations as well as the type of operations.
Below, I collate results across both studies to draw conclusions and suggest areas
for further study.
5.1 Microbial manufacturing is primarily located
in EU and US
A large chunk of microbial manufacturing catering to developed markets is still lo-
cated around Europe and US. Europe leads in manufacturing capacity with over 50%
of global volume. Most of these facilities are large facilities set up before 2002. These
huge investments are unlikely to move ('sticky') and play a large role in Europes
predominance in manufacturing capacity. US on the other hand has only 6 large
manufacturing facilities. US and Europe are comparable in number of facilities. The
strength of US still lies in small innovative facilities performing more clinical man-
ufacture. We see Asia growing but is still a minor player in comparison to US and
Europe. A large part of their growth is due to contract manufacturing organizations
that are doing clinical manufacture.
5.2 The number of operations performed by facil-
ities is higher in US and EU than in Asia
Studies have shown that there are knowledge spillover effects in biomanufacturing.
[13] However, unlike other industries, biomanufacturing is not easily scalable. [21] To
make more products, serve more markets and interact with more regulators is a chal-
lenge. We see in 4.1 that US and EU facilities have learnt to do more without adding
more employees. Employees develop considerable expertise across more products and
operations in high performing facilities. In addition, capacity utilization numbers also
indicate that US (and EU facilities to a lesser extent) have developed within their
operations a greater flexibility to manage multiple products with the same capacity.
This is something that Asian facilities have not yet replicated.
The facilities that perform well on both fronts (more products and more capacity
utilization) are leaders in the field of biomanufacturing, indicating that competitive-
ness in this industry is to a great extent, knowledge-based. Only one Asian facility
features in the top 10 microbial manufacturing locations. All the leading facilities
in terms of capacity utilization and managing many products and markets were US
facilities (followed by EU).
5.3 More complex operations are performed by fa-
cilities in US and EU
[Section 4.4 of this study suggest that facilities in US/EU perform specialize in
upstream processes that are more complex than downstream processing. Even the
upstream processes for US products involve more operations. US facilities manufac-
ture mammalian and microbial products with the highest number of unit operations
indicating that they are at the cutting edge of technology with newest, most com-
plex products and the knowledge and expertise to manufacture them. US facilities
also focus more on process research and are working on more challenging problems
(glycosylation variation) compared to EU facilities that encounter issues during com-
mercial scale manufacture. It was particularly interesting to note that robust process
research in the US can be linked to fewer quality issues. This justifies the claim of
many experts that bio-manufacturing is still an industry that needs support of robust
R&D to succeed.
5.4 There is evidence of clustering and specializa-
tion of facilities across the industry
Data from both the microbial study as well as the survey data indicate that firms
prefer to add products to existing facilities rather than build newer facilities. This
has been suggested in other studies too. [25]
Survey data shows US and EU facilities focus on upstream processes like cell
culture and purification while fill/finish processes have moved to low cost locations
like Asia. There was evidence of specialization in specific kind of processes in fa-
cilities in certain regions. Asian facilities supported simpler processes with fewer
unit operations. However, they supported both upstream and downstream processes
like product packaging. US and EU facilities supported upstream processes like cell
culture and purification which are high value processes and also more complex.
In addition, emergence of CMOs and their rapid growth indicates that biomanu-
facturing may soon become more specialized allowing small biotech to become smaller
and focus on pre-clinical development. Small biotech firms in US and EU focusing on
drug development do not want to bear the risk and cost of setting up manufacturing
facilities. Instead, they hire CMOs or product companies with extra capacity.
The excess capacity and consolidation of the pharmaceutical industry is likely to
assist this process as pharmaceutical firms look to small biotech company to fill up
their pipelines. "Small biotech is about to get smaller, the era of big payouts is over",
said one executive, referring to the lower payout that small biotech companies receive
in licensing deals and acquisitions by large pharma. As firms get more and more
specialized, we can expect large pharma and contract manufacturing firms to do a
lions share of the manufacturing. This is already happening as is evident from the
share of contract manufacturing firms in the top 10 microbial manufacturing regions.
The entry of new players like Samsung and Fujifilm in the contract manufacturing
arena is an interesting development. [7] It would be interesting to see how firms
leverage the expertise from the electronic industry into the biomanufacturing industry.
There appears to be a link between age, expertise of employees and rigorous
process research and productivity, efficiency and product quality and safety of the
facility. These factors are likely to be responsible for clustering of biomanufacturing
around some areas of expertise. Economic and regulatory factors pull manufacturing
in the direction of low cost manufacturing. The combined effect of these factors
may result in the movement of biomanufacturing to newer locations however, it is
unlikely that biomanufacturing, will scatter across various numerous specializations
and geographies. Instead, there may be a more guided flow to certain areas of clusters
of expertise in low cost locations.
5.5 Future work
At the time of writing this thesis the CBI survey was still online. It would be useful to
revisit the analyses in this study once more data on unit operations, capacity utiliza-
tion and quality issues and process types has been collected. Performing statistical
analyses would add weight to these observations made above and also introduce new
metrics and standards for future study. The contract manufacturing industry is set
to play a large role in the innovation and globalization of biomanufacturing. There
are few studies on this topic and much of the evidence that is discussed is anecdotal.
It would be interesting to study from the industry survey as well as other studies,
how contract manufacturing will modify the landscape of biomanufacturing.
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Appendix A
Tables
Table A.1: List of facilities greater than 10kl
Date Company Location Country Firm Capacity Comments
Type
2002 Lilly Indianapolis, USA Product 80,000 Insulin
IN Company
2002 Novo Bagsvaerd Denmark Product 80,000 Insulin
Company
2004 Novo Kalundborg Sweden Product 80,000 Insulin
Company
2004 Biocon Bangalore India Both 60,000 Insulin
2005 Lilly Carolina, USA Product 45,000 Insulin
PR Company
2002 Sanofi-Aventis Frankfurt Germany Product 40,000 Insulin
Company
2002 DSM Biologics Capua Italy Product 70,000
Company
2002 Novartis/Sandoz Kundl Austria CMO 40,000
2002 Amgen Boulder, USA Product 20,000
CO Company
2002 Merck/Schering Brinney, Ireland Product 20,000
Plough Company
2002 Novartis Vacaville & USA Product 20,000
Emeryville, Company
CA
2002 Roche Penzberg Germany Product 20,000
Company
2002 Novartis/Sandoz Kundl Austria CMO 13,000
2002 Pfizer Stockholm Sweden Product 10,000
Company
2002 Roche/Genentech South San USA Product 10,000
Francisco, Company
CA
2004 Lonza Visp Switzerland CMO 30,000
2004 Merck/Diosynth Oss Netherlands CMO 14,000
Biotechnology
2004 Avecia Billingham UK CMO 10,000
2008 Amgen Juncos, PR USA Product 10,000
Company
2012 Avecia Billingham UK CMO 30,000 Planned
2013 Trusgen Biologics Nusajaya, Malaysia CMO 45,000 Planned
I_ I Johor
Table A.2: Statistical significance of the difference in unit operations be-
tween region
Statistical significance of the difference in
unit operations between region
Region P Value Confidence
Asia - EU 0.20 80%
Asia - US 0.06 94%
EU - US 0.13 87%
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Appendix B
Figures
Capacity Utization vs. Number of biologics manufactured in the facility
100% * 2= 0.2471
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# of Biologics Manufactured In the Facility
Figure B-1: Capacity Utilization vs Num of biologics manufactured - Man-
ufacturing more products in a facility may be linked to a need to effectively utilize
excess capacity. As seen in the figure, facilities that manufacture the highest number
of products in a facility also have a high capacity utilization. Mid points of ranges
were used to plot the capacity utilization on the Y axis.
Number of biologics manufactured vs # of Employees
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Figure B-2: Number of biologics manufactured vs Number of employees
in a facility- Little or no correlation between number of employees and number
of biologics manufactured. Facilities that are manufacturing more products are not
doing it with the help of more employees. These facilities build expertise levels that
allow them to be more productive and efficient across more processes and products
with the same number of employees.
# of Product Unit Operations vs % of Lots of Product
Rejected
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Figure B-3: Number of unit operations vs Percentage of total lots rejected
Products with more unit operations tend to face more quality issues or batch to batch
inconsistency.
0 unit operations correspond to 'Not Answered' or NA
Number of biologics manufactured vs
facility
Age of US/ EU
R 2 = 0.4054
10 4020
Age (Years)
Figure B-4: [Number of Biologics vs Age of facility ( US and EU only) - The
correlation between age of facility and number of products manufactures was strong
in US and EU facilities compared to Asia. Setting up new facilities in US and EU is
more expensive than in Asia , there is thus more incentive to cluster manufacturing
and expertise in an existing facility.
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Appendix C
Survey
As a part of the CBI Survey outreach, this text was circulated by Pharma
Manufacturing magazine to its subscribers informing them of the CB1
Survey.
MIT BioMAN Research Program to Examine Quality Approaches in
Biomanufacturing
The Massachusetts Institute of Technologys Biomanufacturing Research Program
(BioMAN) is conducting research to examine the regulatory economics of global bio-
pharmaceutical manufacturing.
When the project is complete, BioMAN will report on the manufacturing char-
acteristics and quality approaches that most impact biopharmaceutical regulatory
compliance. This information will allow biopharmaceutical manufacturing facilities
to benchmark their quality activities and performance against anonymous others.
The MIT CBI is actively looking for interested companies and facilities to partic-
ipate in this research by completing a confidential, secure, and online survey. If you
are interested in participating in the survey, please do so by accessing the following
link: https: //survey. vovici. com/se .ashx?s=664A932C022AC38B
If you have any questions, please contact Dr. Paul Barone at pbaronedmit.edu.
Learn more about the MIT CBI at http://web.mit.edu/cbi/
The survey questionnaire used in the online survey can be seen in
the pages that follow. The 'End of page' refers to the online page in the
survey.
Regulatory Economics of Global Biopharmaceutical Manufacturing
Disclaimer
You have been asked to participate in a research study conducted by the Center for
Biomedical Innovation at the Massachusetts Institute of Technology (M.I.T.).
The purpose of the study is to examine the effect of globalization on biopharmaceutical
product manufacturing regulatory compliance and economics. Our research has been
designed to examine biopharmaceutical manufacturing quality approaches and activities
to understand how manufacturing facility characteristics (e.g. location, experience), FDA
inspection policy (e.g. frequency, extent), and the increasing role of globalization impact
regulatory outcomes. How do company- and firm-level factors impact regulatory
outcomes? Does facility location or experience affect performance? Which
manufacturing quality activities are seen in facilities with the highest regulatory
compliance? When the project is completed we will be in a position to report on the
manufacturing characteristics that most impact biopharmaceutical regulatory
performance.
You were selected as a possible participant in this study as a member of a
biomanufacturing industry with an interest in the questions above.
You should read the information below, and ask questions about anything you do
not understand, before deciding whether or not to participate.
This survey is voluntary.
You have the right not to answer any question, and to stop the interview at any time or
for any reason.
We expect that the survey will take 30 - 60 minutes to complete.
You will not be compensated for this survey.
In any and all publications that may result from this research, the information you tell us
will be confidential.
For participation in the survey, the results of our research will be shared with you in the
form of pre-publication reports.
This project will be completed by December 2011. All survey results will be stored in a
secure work space until 3 years after that date. The records will then be destroyed.
Please contact Paul Barone, pbarone@mit.edu, or Rachna Pande, rachna-p@mit.edu,
with any questions or concerns.
If you feel you have been treated unfairly, or you have questions regarding your rights as
a research subject, you may contact the Chairman of the Committee on the Use of
Humans as Experimental Subjects, M.I.T., Room E25-143b, 77 Massachusetts Ave,
Cambridge, MA 02139, phone 1-617-253-6787.
CONSENT TO PARTICIPATE IN SURVEY
I understand the procedures described above. My questions have been answered
to my satisfaction, and I agree to participate in this study.
O Yes
O No
CONSENT TO PARTICIPATE IN SURVEY I understand the procedures
described above. My questions have been answered to my satisfaction, and I
agree to participate in this study. = No; >>>> Skip to End Page: Survey
Submitted
(End of Page 1)
Instructions
- This survey has six sections.
- Sections 1 - 4 should take 15 - 30 minutes to complete.
- Section 5 asks questions about the specific products produced at this facility. To aid
you in completing this section we have created a data sheet for you to fill out first
(Download Datasheet). With completed data sheets sections 5 and 6 should take 15 -
30 minutes depending on the number of products manufactured in your facility.
- The data sheets can be used to collect data for Q5.6,Q5.7,Q5.8, Q5.15-21, Q5.23 and
Q5.24. You can submit the data sheet instead of entering the data online by emailing the
data sheet to the email address below.
- You will find a progress bar at the bottom of each page to help you gauge how many
questions remain.
- In case you cannot complete the survey in one sitting or you wish to revisit the survey
for any reason, you can save your responses to resume later using the 'Save' button.
NOTE :- You will only be able to access the saved survey through the generated link.
- Use the 'Back' and 'Next' buttons in the panel at the bottom of the page to navigate the
survey
- Use the 'Menu' button to move to any desired page of the survey.
NOTE :- Some of the questions in the latter half depend on your responses to earlier
questions. We strongly recommend you complete the survey in order as far as possible.
- The definition of some specific terms have been included in the survey. These terms
will be underlined with a dotted line. Please hover over the underlined word with your
mouse to view the definition.
- You can submit your responses by clicking on the 'Submit' button on the last page of
the survey.
- Please send an email to Paul Barone (pbarone(@mit.edu) or Rachna Pande
(rachna p(mit.edu) if you have any questions or concerns.
(End of Page 2)
Section One: Manufacturing Facility Information
Q1.1. Manufacturing Facility Information
Company Name
Facility Name
Facility Address (1)
Facility Address (2)
City
State / Province
Postal Code
Country
END OF SECTION ONE
(End of Page 3)
Section Two: Site Details
Q2.1. When did the facility first start production? Please enter approximate date if
not known. (mmldd/yyyy)
Date of first production
Q2.2. Please enter the year when the facility was most recently expanded,
significantly renovated or modified? (yyyy)
Year of most recent expansion/ rennovation/ modification
Q2.3. Please enter the number of years that the facility has been owned by the
current corporation.
Number of years of present ownership
Q2.4. Is this a multi-product site?
O Yes
o No
Q2.5. Please indicate what % of the manufacturing capacity of the facility has
been utilized for contract manufacture?
o 0%
O 1% - 20%
O 21%-40%
0 41% - 60%
0 61% - 80%
0 81% - 99%
0 100%
Advanced Branch: Q2.4 Is this a multi-product
Please enter the following for your facility:
site? = No; >>>> Skip to Page 7:
(End of Page 4)
Section Two: Site Details
Q2.6. How are the different products segregated?
O Product campaigns are segregated by time in the same manufacturing suite /
equipment
o Product campaigns are running on separate equipment / suites
o Both
Advanced Branch: Q2.6 How are the different products segregated? = Product
campaigns are running on separate equipment / suites; >>>> Skip to Page 7:
Was this site designed and built for one or more of the products currently being
manufactured in the facility?
(End of Page 5)
Section Two: Site Details
Q2.7. In your previous response, you stated that product campaigns are
segregated by time in the same manufacturing suites/equipment. What is the
number of product changeovers in a typical year?
Number of product changeovers
(End of Page 6)
Section Two: Site Details
Q2.8. Please enter the following for your facility:
Number of unique biologics currently processed at this site
Number of small molecules currently processed at this site
Q2.9. Please list the unique biologics manufactured in your facility. We will ask
for specific information regarding each biologic in a later section.
Product 1
Product 2
Product 3
Product 4
Product 5
Q2.1 0. Was this site designed and built for one or more of the products currently
being manufactured in the facility?
O Yes
o No
(End of Page 7)
Section Two: Site Details
Q2.1 1. Please indicate the current batch manufacturing capacity of the facility
(total volume of all reactors in liters).
o None
O Less than 1,000
O Between 1,000 and 5,000
O Between 5,000 and 25,000
O Between 25,000 and 50,000
0 Between 50,000 and 100,000
0 100,000 or more
Q2.12. Please indicate the current perfusion manufacturing capacity of the facility
(total volume of all reactors in liters).
0 None
O Less than 100
O Between 100 and 1,000
O Between 1,000 and 10,000
O Between 10,000 and 20,000
0 More than 20,000
(End of Page 8)
Section Two: Site Details
Q2.13. What percentage of the current batch manufacturing capacity mentioned
above is currently being utilized on average? Please use the most recent year for
which data is available to provide an estimate. If you answered "None" on Q2.11,
do not answer.
O < =25%
O 26% to 50%
O 51% to 60%
O 61% to 70%
O 71% to 80%
O 81% to 90%
O 91% to 100%
Q2.14. What percentage of the current perfusion manufacturing capacity
mentioned above is currently being utilized on average? Please use the most
recent year for which data is available to provide an estimate. If you answered
"None" on Q2.12, do not answer.
0 < =25%
O 26% to 50%
0 51% to 60%
0 61% to 70%
0 71% to 80%
0 81% to 90%
0 91% to 100%
(End of Page 9)
Section Two: Site Details
Q2.15. Approximately how many employees currently work at the site?
0 Less than 50
O 51 to 100
O 101 to 500
o >=500
(End of Page 10)
Section Two: Site Details
Q2.16. Which geographic markets are served by the products manufactured from
this facility? Please select all that apply.
LJ USA
LJ Europe
U Canada
U Japan
U South America
U Asia
U Middle East
Q Other (please specify)
Q2.17. Please specify the regulatory bodies that you interact with or have
interacted with in the past. Select all that apply.
Q US - FDA - CDER
Q US - FDA - CBER
U EMA (EU or member countries)
Q Canada
Q Brazil
U Japan
Q Singapore
U China
U India
L Australia
U Other (please specify)
END OF SECTION 2
(End of Page 11)
Section Three: Organization & Function
Q3.1. Do you have a unified company level quality mission statement?
O Yes
O No
O Don't Know
Q3.2. We would like to understand the organizational structure of the facility.
Please indicate the approximate number of people in each of the following
departments in the facility.
Quality Assurance
Quality Control
Engineering Support Services
Manufacturing Dept
Technical Support/ Process Development
(End of Page 12)
Section Three: Organization & Function
Q3.3. We would like to understand how various GMP functional
responsibilities are distributed throughout the organization. Please indicate which
of the following departments are major contributors (> 20% of FTEs) to the
functions listed below by checking the relevant boxes below each department.
Quality Assurance
Change Control Li
CA/PA LJ
Audits(internal) L3
Root Cause Investigations Li
Technology Transfer L3
Raw Material and Intermediate Release Li
Product Release D
Change Control
CA/PA
Audits(internal)
Root Cause Investigations
Technology Transfer
Raw Material and Intermediate Release
Quality Control
Li
L3
Li
Li
Li
Li
Product Release
Change Control
CA/PA
Audits(internal)
Root Cause Investigations
Technology Transfer
Raw Material and Intermediate Release
Product Release
Engineering Support Services
Li
L3
Li
L3
Li
L3
Li
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Change Control
CA/PA
Audits(internal)
Root Cause Investigations
Technology Transfer
Raw Material and Intermediate Release
Product Release
Change Control
CA/PA
Audits(internal)
Root Cause Investigations
Technology Transfer
Raw Material and Intermediate Release
Product Release
Manufacturing Dept
L3
Technical Support! Process
Development
Li
L
(End of Page 13)
Section Three: Quality Activities
Q3.4. At your site, who has final accountability for Quality decisions related to
deviations, corrections and preventive measures?
O QA member assigned to deviation
O QA manager
O Head of QA at the plant
O Plant manager
O Corporate QA or corporate office (not at plant)
O Departmental deviation owner
O Other (please specify)
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Q3.5. In your firm, please identify who is most accountable for Quality decisions
related to deviations, corrections and preventive measures?
O QA member assigned to deviation
o QA manager
O Head of QA at the plant
O Plant manager
O Corporate QA or corporate office (not at plant)
O Product manager
O Other (please specify)
Q3.6. On a scale of 1 - 5, 1 being "No experience" and 5 being "Extensive
experience", how much experience does this facility have with root cause
investigations?
1 - No experience 2 3 4
Site experience with
root cause
investigations
5 - Extensive
experience
0 0 0 0
(End of Page 14)
102
Section Three: Quality Activities
Q3.7. Based on your experience and understanding, what have been the main
drivers for quality activities or resource allocation in the past? Which drivers do
you expect to play a role going forward?
Key driver in the past
Yes No
Problems in raw material O
Problems in equipment 0
Regulatory noncompliance O
Problems in production
process
Process change due to scale
up
Process change due to new
technology
Process change due to new
markets
Process change due to
management objective
Process change due to cost
reduction
Process change due to other
reasons
Changes to maintain cGMP
status when anticipating
regulatory changes 0
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Future role expected
Yes
Problems in raw material
Problems in equipment
Regulatory noncompliance
Problems in production
process
Process change due to scale
up
Process change due to new
technology
Process change due to new
markets
Process change due to
management objective
Process change due to cost
reduction
Process change due to other
reasons
Changes to maintain cGMP
status when anticipating
regulatory changes
(End of Page 15)
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No
Section Three: Quality Activities
Q3.8. On a scale of I to 5, 1 being "No multidisciplinary teams exist" and 5 being
"Extensive multidisciplinary teams", please indicate how you approach internal
quality activities such as Change Control, CA/PA, Audits, Root Cause
Investigations, Validation, Technology Transfer, Raw Material and intermediate
release and Product Release?
1- No
multidisciplinary
teams 2 3 4
5 - Extensive
multidisciplinary
teams
Teams for
internal quality
activities 0 0 0 0
Q3.9. Which of the following are typically involved in the quality teams specified
above?
L Central R&D
L Managers/ Supervisors
Q Operators
L Administrators
L Technicians
Q Craft workers
L Engineers
(End of Page 16)
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Section Three: Product Transfer and Continuous Improvement
Q3.1 0. On average, how many scientists or engineers at the facility are involved
in a typical incoming product transfer process? Product transfer for this purpose
is defined as beginning with the commitment of product to a particular site and
ending with the final process validation run.
O 1 to 5
o 5 to 15
0 > 15
Q3.1 1. How many months, on average, is each scientist or engineer involved in a
typical product transfer process? Product transfer for this purpose is defined as
beginning with the commitment of product to a particular site and ending with the
final process validation run.
O < 1 month
O 1 -6 months
O 6 months - 1 year
O 1 year - 2 years
O > 2 years
Q3.12. What has been the role of manufacturing innovation in your site?
O No Role
O Some role
0 Major role
(End of Page 17)
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Section Three: Deviations and Root Cause Investigations
Q3.13. How many months, on average, are required for corrective/preventive
action to be put in place following a typical critical deviation at your
manufacturing facility/site?
O Less than 1 month
O Between 1 and 6 months
O Between 6 and 12 months
O More than 12 months
Q3.14. What percentage of the total operating budget for the site, over the past 5
years, has been expended on QA/QC/regulatory affairs?
O Less than 25%
O Between 25% and 40%
O Between 40% and 55%
O More than 55 %
Q3.15. What percentage of the total FTE time, over the past 5 years, has been
expended on training?
O Less than 2%
O Between 2% and 5%
O Between 5% and 10%
O Between 10% and 15%
O More than 15 %
END OF SECTION 3
(End of Page 18)
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Section Four: Interaction with Regulatory Bodies
Q4.1. What is the frequency of inspections (in months), on average, for the
following regulatory bodies? (e.g. 6 would indicate every 6 months, if you have
never been inspected by the authority, please enter zero)
US- FDA-CDER
US-FDA-CBER
EMA (EU or member
countries)
Canada
Brazil
Japan
Singapore
China
India
Australia
%Q13SPECIFIED_11%
108
Q4.2. On a scale of I to 5, 1 being 'Highly challenging' and 5 being 'Highly
collaborative', please summarize your interactions with each regulatory body.
Enter your answers at right, fractional answers are accepted (e.g. 4.5).
1- Highly Challenging 2 3 4 Highly Collaborative -5
US- FDA-CDER
US-FDA-CBER
EMA (EU or member
countries)
Canada
Brazil
Japan
Singapore
China
India
Australia
%Q13SPECIFIED_11%
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Q4.3. What is your perception of the site's standing with the FDA?
o Poor
O Below Average
o Average
O Above Average
O Good
Q4.4. Assuming there to be a varying degree of stringency across all the regulatory
bodies, please rank the top 5 in order of more stringent to less stringent. Drag the
items in the list on the left into the box on the right. (The top regulatory body is most
stringent)
US - FDA - CDER
US - FDA-CBER
EMA (EU or member countries)
Canada
Brazil
Japan
Singapore
China
India
Australia
%Q13SPECIFIED_11%
(End of Page 19)
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Section Four: Interaction with Regulatory Bodies
Q4.5. To what degree do you agree with the following statement: there is consistency
between FDA and EMA inspections.
1- 3-Neither 5 -
Strongly 2 - agree nor 4- Strongly
Disagree Disagree disagree Agree Agree
There is
consistency
between FDA
and EMA
inspections. O O 0 0 0
Q 4.6. On a scale of 1-5, where I is "Strongly Disagree" and 5 is "Strongly Agree",
please rate the following:
3-
1 - Neither 5 -
Strongly 2 - agree nor 4- Strongly
Disagree Disagree disagree Agree Agree
There is
significant
variation
across FDA
inspectors 0 0 0 0 0
There is
significant
variation
across EMA
inspectors 0 0 0 0 0
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Q4.7. Apart from the documentation, does your site prepare for inspections with
the FDA and EMA differently?
O Yes
O No
Advanced Branch: Q4.7 Apart from the documentation, does your site prepare
for inspections with the FDA and EMA differently? = No; >>>> Skip to Page 22:
Do you involve the central off-site R&D department with the following
inspections? Please check all those applicable.
(End of Page 20)
Section Four: Interaction with Regulatory Bodies
Q4.8. Please explain briefly how your preparation for inspections with the FDA and
EMA differ.
(End of Page 21)
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Q4.9. Do you involve the central off-site R&D department with the following
inspections? Please check all those applicable.
Informed Involved
Neither
informed not
involved
Routine
Surveillance
Inspections
Compliance
Inspections
Pre-
Approval(drugs)/
Pre-license
(biologics)
For cause
Inspections
(End of Page 22)
Section Four: Regulatory Affairs
Q4.10. How many regulatory affairs FTEs are dedicated to supporting the facility?
Dedicated regulatory affairs FTEs supporting the facility
Q4.1 1. On a scale of 1 - 5, 1 being 'Not involved' and 5 being 'Extensively involved in
all steps', please rate the involvement of the regulatory affairs department in the
following inspections.
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1 - Not
involved at all 2 3 4
5-
Extensively
involved in all
steps
Internal
Inspections
Third Party
Inspections
Routine
Surveillance
Inspections
Compliance
Inspection
Pre-approval
(drugs)/ Pre-license(biologics)
For Cause
Inspections
O0000
O0000
O0000
O0000
0000O
O0000
Q4.12. On a scale of 1 - 5, 1 being "Not involved' and 5 being "Extensively involved in
all steps', please rate the involvement of the regulatory affairs department in process
development?
Not Involved 2 3 4
Extensively
involved in all
steps
Involvement of
regulatory affairs
in process
development 0 0 0 0
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Q4.13. At what stage is the regulatory affairs department involved in product
development?
O Chemistry, Manufacturing and Controls (CMC)
O Product development - Clinical
O Product development - Pre Clinical
O Commercialization
Q4.14. How does the regulatory affairs department stay updated with FDA
developments?
U Meetings with FDA
Q Regular trainings - prescribed by FDA
U Memos circulated
U Other
Q4.15. Do you assess the performance of the regulatory affairs department in a
well-defined way?
O Yes
O No
Q4.16. Please explain in brief the process for assessing the performance of the
regulatory affairs department.
(End of Page 23)
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Section Four: Internal and External Audits
Q4.17. Is an internal audit team involved in preparation for the following
inspections? Please check all that apply.
U Routine Surveillance Inspections
U Compliance Inspection
Q Pre-Approval (drugs)/Pre-License (biologics)
U For-Cause Inspections
Q4.18. Has the site had any inspections from a third party (i.e neither internal nor
regulatory)?
OYes
O No
Advanced Branch: Q4.18 Has the site had any inspections from a third party (i.e
neither internal nor regulatory)? = No; >>>> Skip to Page 26: NOTE: Before you
proceed please ensure that you have answered question Q2.8 and Q2.9 on Page 7
correctly and completely.
Q2.8 Number of unique biologics curently processed at this site: %[Q2.8]Q5 1%
Q2.9 List of biologics currently manufactured at this site:
Product1
%[Q2.9]Q18_2%
%[Q2.9]QI8_3%
%[Q2.91Q184%
%[Q2.9]Q18_5%
(End of Page 24)
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Section Four: Interaction with Regulatory Bodies
Q4.19. If so, how many third party inspections has the site had over the last five
years?
END OF SECTION 4
(End of Page 25)
Section Five: Product Specific Section
All questions in the next section are specific to the biologics manufactured in your site.
You will be asked to answer this section for each of the products you specified. (i.e if you
entered 2 products, you will be asked to answer this section twice.)
NOTE: Before you proceed please ensure that you have answered question Q2.8 and
Q2.9 on Page 7 correctly and completely.
Q2.8 Number of unique biologics curently processed at this site: %[Q2.8]Q5 1 %
Q2.9 List of biologics currently manufactured at this site:
Product1
%[Q2.9]Q18_2%
%[Q2.9]Q18_3%
%[Q2.9]Q18_4%
%[Q2.9]Q18_5%
El Please check the box if the above info is answered correctly. If not, please use
the menu button to update your response on page 7.
Advanced Branch: Q2.8 (Number of unique biologics currently processed at this
site) = 0; >>>> Skip to Page 57: How would you describe the awareness of the
firm/ facility to academic research and training in biomanufacturing? Please
choose one of the following options:
(End of Page 26)
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Section Five Product 1
Note : This section was repeated for 5 products
Q5.1. Please indicate the Molecule Type for Product1 in this facility. Select all that
apply.
LJ Protein
U DNA/ RNA
U Antibody
Q Vaccine
Q Small Molecule
Q Drug Substance
U Drug Product
Q5.2. Please indicate the Cell Tve that is relevant for manufacturing Product1 in
this facility. Select all that apply.
Q Mammalian
U Microbial
Q Egg Based
Q Viral Vector
U Other
Q5.3. Please indicate the Process Tvoe that is relevant for
manufacturing Product1 in this facility. Select all that apply.
Q Cell Culture
U Fermentation
U Plasma Fractionation
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LJ Purification
LJ Fill/ Finish
L Product Packaging
Q5.4. Please indicate
Select all that apply.
L Drug Substance
L Drug Product
U Intermediate
the Product Form of Product1 when it leaves this facility.
(End of Page 27)
Section Five Product Complexity
Q5.5. On a scale of I to 5, 1 being "Very simple" and 5 being "Highly complex", how
would you rate the complexity of manufacture of Product1 at this site relative to other
biopharmaceutical products in general (not necessarily in the same facility)?
1 - Very
simple 2 3 4
5 - High
complex
Complexity of
manufacture of the
product at this site
relative to other
biopharma-ceutical
products 0 0 0 0
Q5.6. Please specify the number of unit operations for each of the following steps
relevant to Product1 at your site.
Cell culture
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Purification
Fill / Finish
Q5.7. Please specify the number of distinct Critical Process Parameters (CPPs) in
each of the following steps for ProductI.
# of distinct CPPs in Cell Culture
# of distinct CPPs in Purification
# of distinct CPPs in Fill Finish
Q5.8. How many Critical Quality Attributes (CQAs) are there for Product1?
Number of Distinct CQAs
(End of Page 28)
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Section Five Product 1 Quality
Q5.9. What types of quality issues has Product1 faced during development?
Q Product variation (e.g. glycosylation variation)
Q Contamination (e.g. related to biologocal contaminants virus etc.)
Q Impurities (e.g. host cell protein)
L Cell line related
U None of these
Q5.9 - 2. If you selected "None of these" for Q5.9, please briefly describe what other
quality issues Product1 has faced during development. If there were no quality issues,
please enter "None".
Quality Issue
Q5.10. When have these quality issues surfaced?
U Discovery
Q Process Research
Q Pilot development
L Commercial plant transfer and start up
Li Full scale production
LQ Assay development
Li Other
(End of Page 29)
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Section Five Product 1 Innovation
Q5.1 1. What has been the role of the following in the manufacturing of Product1?
Role in the past
No Role Some Role Major Role
Role of
continuous
improvement
of
manufacturing
for Product1 0 O O
Role of QbD
Submissions
for Product1 0 0 0
Expected Role in the Future
No Role Some Role Major Role
Role of
continuous
improvement
of
manufacturing
for Product1 0 0 0
Role of QbD
Submissions
for Product1 0 0 0
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Q5.12. On a scale of I to 5, 1 being "No effect/never used" and 5 being "Highly
effective/often used", please indicate the perceived effectiveness of the following
processes for Producti:
1 - No Effect/
Never used
MIS in
manufacturing for
your site/firm
Multivariate data
analysis in
manufacturing
PAT in
manufacturing
2 3
5 - Highly
Effective/
4 Often Used
O  0 O
0 O 0 0
0 0 0
(End of Page 30)
Section Five Product 1 Manufacture
Q5.13. How would you define the frequency of manufacture for Product1?
O Regular Basis
O Infrequent Basis
Q5.14. For Product1, in which of the following stages have you used single use
reactors? Check all that apply.
L Not used at all
L Discovery
Q Process development
L Clinical development
Q Commercial plant transfer and start up
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L3 Full Scale Production
U Assay Development
U Other (Please Specify)
Q5.15. In the past year, for Producti, approximately what is the number of lots
released?
o 1 to 10
010-25
0 25 - 50
0 50 - 100
0100-200
0 > 200
Q5.16. In the past year, for Producti, approximately what percentage of lots have
been rejected?
0 0%
Q 0.1% - 0.5%
0 0.5% - 1%
0 1%-3%
0 > 3%
Q5.17. How many total lots of Product1 has the site produced in the past 5 years?
Total # of lots of Product1
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Q5.18. For Producti, how many deviations have occurred at the site in the past 5
years?
Total # of deviations over 5 years
Q5.19. For Producti, what % of the total deviations in the past 5 years were critical?
(involved critical process parameters and/or critical quality attributes)
% of critical deviations
Q5.20. For Product1, what % of critical deviations in the past 5 years had no
assignable causes found?
% of deviations with no assignable cause
Q5.21. For Producti, what % of the critical deviations in the past 5 years were
associated with your analytical/measurement systems?
% of critical deviations associated with analytical / measurement systems
(End of Page 31)
Section Five Product 1 Manufacture
Q5.22. Over the past 5 years, how would you describe the trend seen in
manufacturing volume for Product1?
o Steadily increasing
0 Steadily decreasing
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0 More or less Stable
O Fluctuating
Q5.23. What is the annual average production of Product1 at this site (in kilograms)?
Annual average production of Product1
Q5.24. Was Product1 produced at a similar scale at a different site previously?
O Yes
O No
O Don't Know
Advanced Branch: Q2.8 (Number of unique biologics currently processed at this
site) : 1; >>>> Skip to Page 57: How would you describe the awareness of the
firm/ facility to academic research and training in biomanufacturing? Please
choose one of the following options:
(End of Page 32)
Section Six: Academic Role in Biomanufacturing
Q6.1. How would you describe the awareness of the firm/ facility to academic
research and training in biomanufacturing? Please choose one of the following
options:
0 Not Aware
O Aware that such research and training exists but currently not involved
0 Currently actively involved in the academic research and training
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Q6.2. Please identify the locations of academic biomanufacturing research and
training facilities/capabilities that you are aware of.
Location 1
Location 2
Location 3
Location 4
Location 5
Q6.3. On a scale of I to 5, where 1 is "Not at all important" and 5 is "Extremely
important", how important is geographic proximity of an academic site to the
manufacturing site for engaging in academic biomanufacturing research and
training?
Importance of
proximity of
academic site for
engaging in
academic bio-
manufacturing
research and
training
1 - Not
important at all
0
5 - Extremely
2 3 4 important
0 0 0 0
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Q6.4. On a scale of I to 5, where 1 is "No value at all" and 5 is "Extremely high value",
what value do you believe academic biomanufacturing research and training has?
1 - No value at
all
Value of academic
bio-manufacturing
research and training
5 - Extremely
2 3 4 high value
0 0 0 0
Advanced Branch: Q6.1 How would you describe the awareness of the firm/
facility to academic research and training in biomanufacturing? Please choose
one of the following options: ; Currently actively involved in the academic
research and training; >>>> Skip to Page 58: What areas of academic
biomanufacturing research and training do you believe to be of most value?
(End of Page 57)
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Section Six: Academic Role in Biomanufacturing
Q6.5. Please identify the locations of academic biomanufacturing research and
training facilities that your site interacts with.
Location 1
Location 2
Location 3
Location 4
Location 5
Q6.6. On a scale of 1 to 5, where I is "Do not use at all" and 5 is "Use on a regular
basis", please specify to what extent you use academic biomanufacturing research
and training?
1 - Do not
use at all
Extent to which you
use academic bio-
manufacturing
research and
training
5 - Use on a
2 3 4 regular basis
0 0 0 0
Q6.7. What areas of academic biomanufacturing research and training do you
believe to be of most value?
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06.8. In what areas do you think academic biomanufacturing research and
training needs are currently not being addressed and would be of most value to
industry?
Q6.9. To maximize current and/or potential value from academic biomanufacturing
efforts, which of the following is best to focus on
L Research in relevant management and regulatory topics
U Training in relevant management and regulatory topics
L Research in relevant technical and engineering topics
Q Training in relevant technical and engineering topics
Q None of the above
END OF SURVEY
You have completed the survey. Please click on the SUBMIT button below to submit
your responses and close the survey.
NOTE: Once you submit your survey you will no longer be able to access/modify your
responses. If you wish to revisit your survey or modify responses later please go to
any other page of the survey to save the survey using the SAVE button.
(End of Page 58)
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